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ABSTRACT
DETECTION OF ANEUPLOIDY FOR CHROMOSOMES 7 AND 8 
USING FLUORESCENCE IN SITU HYBRIDIZATION IN 
PATIENTS WITH APLASTIC ANEMIA AND SEQUENCING 
OF THE MITOTIC CHECKPOINT GENE hBUBl
Laura Jane Aridgides 
Old Dominion University, 2001 
Director: Dr. Christopher Osgood
Aplastic anemia (AA) is characterized by complete bone 
marrow failure. Progression to myelodysplastic syndromes 
(MDS) and acute nonlymphocytic leukemia (ANLL) occurs 
frequently. At the time of transformation, cytogenetic 
abnormalities are common. Detection of cytogenetic 
abnormalities prior to leukemic transformation may indicate 
future disease progression. Karyotype analysis is the 
current method of choice to evaluate chromosome 
aberrations. However, fluorescence in situ hybridization 
(FISH) is more sensitive in detecting these abnormalities.
hBUBl, a mitotic spindle checkpoint gene, was shown to be 
mutated in two colorectal cancer cell lines with high 
levels of aneuploidy (Cahill, et al., 1998). Although 
theoretically possible, conclusive evidence does not 
currently exist establishing a link between aneuploidy 
levels and mutations within a mitotic spindle checkpoint
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
gene. hBUBl is the most characterized of the mitotic 
checkpoint genes.
FISH was used to detect cytogenetic abnormalities for 
chromosomes 7 and 8 in bone marrow samples from patients 
with AA. In addition, ribonucleic acid (RNA) from all 
patient samples also underwent hBUBl-specific reverse 
transcription polymerase chain reaction (RT-PCR) , followed 
by sequencing of the RT-PCR product. Statistical analyses 
were performed on FISH and sequencing results. Additional 
samples from patients with a variety of bone marrow 
disorders also underwent hBCTBI-specific RT-PCR and 
sequencing without FISH analysis.
Seven patient samples out of 4 6 (15.2%) showed elevated 
levels of aneuploidy for chromosomes 7, 8, or both. Four 
of the seven samples showed abnormalities previously 
undetected by a karyotype analysis. This indicates that 
FISH analysis is approximately twice as sensitive as a 
karyotype analysis, and may assist in earlier diagnosis and 
proper treatment of patients with AA. Statistical analysis 
showed an increased level of monosomy 8 in African-American 
males. The age of the patient and responsiveness to 
treatment did not correlate with the level of aneuploidy. 
Results from the h-BUBl-specif ic RT-PCR and sequencing were 
inconclusive due to the high probability of Taq-induced PCR
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artifact, however there was no apparent correlation between 
the presence of aneuploidy and the sequencing results. 
Seventy-eight to 85% of all patient samples analyzed did 
not amplify any hBDBl-specific RT-PCR product.
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ABBREVIATIONS
AA = aplastic anemia
AL = acute leukemia
AML = acute myeloid leukemia
Amp = ampicillin
ANLL = acute nonlymphocytic leukemia
APC = anaphase promoting complex
ATG = antithymocyte globulin
BUB = budding uninhibited by benzimidazole
CD = cluster of differentiation
CDC = cell division cycle
cdk = cyclin-dependent kinase
cDNA = complimentary DNA
CFU = colony-forming unit
CIN = chromosomal instability
CKI = cyclin-dependent kinase inhibitor
CMML = chronic myelomonocytic leukemia
CsA = cyclosporin A
DAPI = 4',6-diamidino-2-phenylindole 
DNA = deoxyribonucleic acid
EDTA = disodium ethylenediamine tetraacetate 
Epo = erythropoietin 
FA = Fanconi's anemia
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FAB = French., American, and British 
FISH = fluorescence in situ hybridization 
gal = galactosidase
G-CSF = granulocyte colony-stimulating factor
GM-CSF = granulocyte-macrophage colony-stimulating factor
GPI = glycosylphorphatidylinositol
GVHD = graft versus host disease
IL = interleukin
INF = interferon
IPTG = isopropyl {3-D-thiogalactopyranoside
LB = Lennox broth
MAD = mitotic arrest deficient
MBG = molecular biology grade
M-CSF = macrophage colony-stimulating factor
MDS = myelodysplastic syndromes
MI = mitotic index
MIN = microsatellite instability
MPF = maturation (M phase) promoting factor
MPS = monopolar spindle
MTOC = mictotubule organizing center
Nal = sodium iodide
NK = natural killer cell
PBS = phosphate buffered saline
PCR = polymerase chain reaction
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X
PNH = paroxysmal nocturnal hemoglobinuria 
RA = refractory anemia
RAEB = refractory anemia with excess blasts 
RAEB-t = refractory anemia with excess blasts in 
trans formation 
RARS = refractory anemia with ringed sideroblasts 
Rb = retinoblastoma 
RNA = ribonucleic acid
RT-PCR = reverse transcription polymerase chain reaction
SAA = severe aplastic anemia




TGF = transforming growth factor
t-MDS = therapy-related myelodysplastic syndromes 
TNF = tumor necrosis factor 
TPO = thrombopoietin
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Hematopoiesis is defined as "the formation and 
development of blood cells involving both proliferation and 
differentiation from stem cells (Online Medical Dictionary, 
2001) The stem cells necessary for successful 
hematopoiesis begin to form in the yolk sac during early 
gestation, and migrate to the liver and the spleen before 
settling within the bone marrow. It is in the bone marrow 
that the majority of hematopoiesis occurs in healthy 
individuals (Sullivan, 2001). However, most of the stem 
cells within the bone marrow are in a quiescent state 
(Jordan and Van Zant, 1998; Sullivan, 2001). A portion of 
the cells undergo self-renewal, but only a tiny fraction of 
the cells are differentiating at any given time (Sullivan, 
2001) .
The model for this dissertation is the journal Cell.
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Stem Cell Differentiation
All cells differentiate from a totipotent stem cell 
(Peterson, 1995; Sachs, 1996) . The totipotent stem cell 
has the potential to travel down the myeloid 
differentiation pathway, the lymphoid differentiation 
pathway, or to undergo self-renewal (Klumpp, 2001;
Sullivan, 2001). The mechanism that determines the cell's 
fate is unclear, but it is thought to be either stochastic 
(random) or induced by external stimuli (cell to cell 
interactions and/or cytokines) (Enver et al., 1998) . When 
the decision is made to differentiate, the stem cells 
become multipotent myeloid or lymphoid stem cells. The 
multipotent stem cells give rise to progenitor cells called 
colony-forming units (CFU) (Klumpp, 2001; Sullivan, 2001). 
The myeloid pathway is further subdivided into the 
erythroid, megakaryocytic and phagocytic branches. The 
erythroid pathway ends in the formation of erythrocytes, 
and the megakaryocytic pathway ends in the formation of 
platelets. The phagocytic pathway subdivides even further 
into granulocytic and monocytic pathways. The granulocytic 
pathway divides once more into the neutrophilic, 
eosinophilic and basophilic pathways, which end in the 
formation of neutrophils, eosinophils and basophils,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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respectively. The monocytic pathway ends in the formation 
of macrophages (Sullivan, 2001).
The lymphoid pathway is also subdivided into the B cell 
pathway, the T cell pathway and the non-B, non-T cell 
pathway. The B cell pathway ends in the formation of B 
cells, and the T cell pathway ends in the formation of T 
cells. The non-B, non-T cell pathway ends in the formation 
of natural killer (NK) cells (Peterson, 1995; Sullivan, 
2001) (Figure 1). The cluster of differentiation (CD) 
antigens presented on each cell's surface can assist in 
identification of the different cell types (Sears, 1997) .
The Role of Cytokines in Hematopoiesis
Cytokines can act as growth factor hormones that 
orchestrate the production of cells during hematopoiesis. 
Each cytokine acts upon one or more specific cell types.
To elicit a response, the cell must have a receptor 
specific for the cytokine. There are a wide variety of 
cytokines including, but not limited to: erythropoietin 
(Epo), thrombopoietin (TPO), granulocyte-macrophage colony- 
stimulating factor (GM-CSF) , granulocyte colony-stimulating 
factor (G-CSF), macrophage colony-stimulating factor (M- 
CSF), stem cell factor (SCF), tumor necrosis factor alpha
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Erythroid progenitor Erythrocyte
Figure 1. Overview of Hematopoiesis, Including Cytokine 
Interactions.
Photograph taken from http://www.whfreeman.com/kuby
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(TNF-a) , transforming growth factor beta (TGF-0) , and a 
variety of interleukins (IL) (Klumpp, 2001; Moqattash and 
Lutton, 1998; Sachs, 1996; Sullivan, 2001). There are 
cytokines thiat induce hematopoiesis (such as GM-CSF and IL- 
2) and there are cytokines that inhibit hematopoiesis (such
as TGF-3, IIL-10 or interferon gamma (INF-y) ) (Moqattash and 
Lutton, 1998; Sachs, 1996). The mechanism of stimulation 
or inhibition may be direct or indirect, and may involve 
multiple cytokines acting together to achieve the final 
outcome (Mocqattash and Lutton, 1998) . A triad comprised of 
stem cells, cytokines and the bone marrow stroma works 
together to achieve hematopoiesis (Enver et al., 1998; 
Moqattash and Lutton, 1998; Orkin, 1996; Sullivan, 2001). 
The hematopoietic progenitor cells adhere to the bone 
marrow stroma enabling them to receive cytokine signals 
from the stroma. Leukemic cells also rely on adhesion to 
the stroma matrix to increase survival and reduce the 
likelihood of apoptosis (Greer and Kinney, 1993; Moqattash 
and Lutton, 1998; Sachs, 1996). A defect in any component 
of the hematopoietic triad creates the potential for blood- 
related diseases, such as leukemia (Moqattash and Lutton, 
1998; Sachs, 1996).
It is of interest to report on some of the more common 
cytokines and their actions on normal cell growth; however,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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a complete review is beyond the scope of this manuscript. 
Epo is involved in erythropoiesis by stimulating 
differentiation of erythroid colony-forming units (CFU-E) 
and increasing red blood cell production (Moqattash and 
Lutton, 1998; Sullivan, 2001) . TPO stimulates 
megakaryocytes and, as a result, increases the number of 
platelets (Moqattash and Lutton, 1998). GM-CSF in 
combination with SCF can stimulate various hematopoietic 
pathways. G-CSF stimulates the differentiation of 
leukocytes. M-CSF stimulates the differentiation of 
monocytes. A variety of IL cytokines can assist other 
cytokines in the stimulation or inhibition of various 
hematopoietic pathways (Moqattash and Lutton, 1998; Sachs, 
199 6). There is a tremendous complex cytokine network that 
has a direct impact on hematopoiesis, of which all 
functions are not yet known or completely understood.
Cytokines have been implicated in leukemic 
transformation, which is characterized by uncontrolled cell 
growth. This can be due to inhibition of apoptosis or an 
increase in hematopoiesis (Israels and Israels, 1999; 
Wickremasinghe and Hoffbrand, 1999). Since cytokines are 
involved in both apoptosis (cell death) and hematopoiesis 
(inducing cell growth and differentiation), it can be 
inferred that abnormal cytokine production may contribute
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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to the formation of cancer (Israels and Israels, 1999; 
Moqattash and Lutton, 1998). For example, it has been 
reported that IL-8 can stimulate bcl-2 expression in cells 
from patients with B-cell chronic lymphocytic leukemia. 
Increased levels of bcl-2 help protect the cancerous cells 
from apoptosis (an increased level of bcl-2 has also been 
reported in patients with myelodysplastic syndromes (MDS)) 
(Israels and Israels, 1999; Moqattash and Lutton, 1998; 
Sachs, 1996; Wickremasinghe and Hoffbrand, 1999). Cytokine 
effects on leukemic cells are incredibly variable and have 
been shown to elicit different responses in different 
patients (Marsh, 2000; Moqattash and Lutton, 1998).
Cytokines have recently been investigated for clinical 
use in patients with hematological disorders, the caveat 
being that cytokines can also decrease the effectiveness of 
some anticancer agents by inhibiting apoptosis (Marsh,
2000; Moqattash and Lutton, 1998; Sachs, 1996; 
Wickremasinghe and Hoffbrand, 1999). Studies showed that 
patients with MDS treated with G-CSF and Epo resulted in an 
increase in hematopoiesis. On the other hand, treatment 
with growth factors can also inhibit apoptosis of leukemic 
cells, which is manifested as a poor response rate to some 
chemotherapeutic agents (Moqattash and Lutton, 1998; Sachs 
1996).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8
BONE MARROW FAILURE SYNDROMES
Although aplastic anemia (AA) is the primary focus of this 
manuscript, and is reviewed in detail below, other bone 
marrow disorders are mentioned in conjunction with AA, and 
therefore deserve explanation.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
PNH is a clonal stem cell disorder characterized by 
cells deficient in glycosylphosphatidylinositol (GPI)- 
anchored proteins (Dunn, et al., 1999; Socie, et al.,
2000). The traditional phenotypic marker of dark-colored 
urine occurs in about half of the patients diagnosed with 
PNH, and is caused by intravascular hemolysis. Hemolysis 
occurs due to an increase in compliment (immune-mediated 
cell lysis) as a direct result of the deficiency in GPI- 
anchored proteins (Dunn, et al., 1999; Lee, 1993) . This 
deficiency is caused by a somatic mutation in the PIG-A 
gene located on the X chromosome (Dunn et al., 1999; Socie, 
et al., 2000).
There are three types of PNH cells, type I, type II and 
type III, all of which show various sensitivity levels to 
complement. Patients with PNH may present with AA-like 
symptoms (pancytopenia with hypoplastic marrow) or MDS-like
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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symptoms (pancytopenia with cellular marrow), and 
cytogenetic analyses have not provided any diagnostic 
chromosomal patterns. PNH is associated with a high rate 
of thromboses, which may be fatal, and renal abnormalities 
(mainly due to hepatic thromboses) . Other than bone marrow 
transplantation, which is rarely used to treat patients 
with PNH, there is no definitive treatment regimen.
Complete remission is only achieved in a small number of 
patients (Lee, 1993).
Recent reports show that approximately 22-23% of 
patients with AA or MDS also suffer from PNH (Dunn, et al., 
1999). Originally, it was thought that PNH was a late 
complication of AA and MDS, however more recent data show 
that cells deficient in GPI-anchored proteins (detected by 
flow cytometry) are present at the time of diagnosis with 
AA or MDS (Colby et al., 1996; Dunn, et al., 1999; Socie,
et al., 2000; Tisdale, et al., 2000; Young, 2000). Cells 
deficient in GPI-anchored proteins were not detected in 
patients treated with antithymocyte globulin (ATG) for 
reasons other than AA or MDS (Dunn, et al., 1999). This 
suggests that there is no correlation between ATG therapy 
and the presence of cells lacking GPI-anchored proteins 
(Dunn, et al., 1999; Socie, et al., 2000). However, MDS 
patients who express cells without GPI-anchored proteins
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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respond better to treatment with immunosuppressive therapy, 
and recent experiments by Dunn et al- showed that cells 
which are deficient in GPI-anchored proteins are less 
affected by an autoimmune attack (Dunn et al., 1999). This 
phenomenon may explain why the onset of PNH may be linked 
with the presence of a bone marrow failure disorder (AA or 
MDS) that is thought to be a result of an autoimmune 
attack. Since cells lacking GPI-anchored proteins show 
resistance to attack by the immune system, they may be 
preferentially selected for in the case of such an attack.
Myelodysplastic Syndromes (MDS)
The MDS are a group of clonal disorders that can occur 
de novo, or may occur following treatment for AA (secondary 
MDS). They are characterized by anemia that does not 
respond to treatment (Deiss, 1993) . Secondary MDS has a 
characteristic pattern of evolution wherein hematopoiesis 
is restored (at least partially) after treatment for AA, 
followed by a subsequent decline and the onset of MDS or 
other disorders (see PNH section above) (De Planque et al., 
1988; Socie et al., 2000). MDS is associated with an older 
age group, and is slightly more common in males (Barrett et 
al., 2000; Deiss, 1993). There are five categories of MDS 
as defined by the French, American, and British (FAB)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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group: refractory anemia (RA) , refractory anemia with 
ringed sideroblasts (RARS), refractory anemia with excess 
blasts (RAEB), refractory anemia with excess blasts in 
transformation (RAEB-t) , and chronic myelomonocytic 
leukemia (CMML) (Deiss, 1993) . Of these subsets, patients 
diagnosed with RAEB or RAEB-t are more likely to undergo 
leukemic transformation. Unfortunately, classification is 
based on phenotypic markers alone, and the presentation of 
MDS can often be misdiagnosed as AA and vice versa (Barrett 
et al., 2000; Dunn et al., 1999; Socie et al., 2000) . MDS 
often presents clinically with one or more cytopenias 
(anemia, pancytopenia, thrombocytopenia, or neutropenia) 
present at the time of diagnosis (Barrett et al., 2000; 
Deiss, 1993) . In addition, cytogenetic abnormalities are 
commonly found at diagnosis, including 5q-, monosomy 7 and 
trisomy 8. A complex karyotype, or the presence of 
monosomy 7 is considered to be a poor prognosis (Barrett et 
al., 2000; Deiss, 1993; Socie et al., 2000) . It is 
estimated that 10-25% of patients with MDS will progress to 
acute nonlymphocytic leukemia (ANLL). The development of 
MDS may be due to immunosuppressive therapy for a prior 
malignancy (therapy-related MDS (t-MDS)) (Deiss, 1993;
Socie et al., 2000). In t-MDS, a greater percentage of 
patients have complex cytogenetics, do not respond well to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
12
treatment, and a larger percentage undergo transformation 
to ANLL (Deiss, 1993) .
Many patients are asymptomatic, and chemotherapy is 
usually unsuccessful. It is hard to evaluate the 
effectiveness of various treatment regimens due to the lack 
of large randomized trials with patients of the same 
disease category (de novo versus secondary MDS, etc.). 
Remission is attained in approximately 50% of patients with 
MDS, however relapse is very common and occurs rapidly.
Bone marrow transplant is an available option for some 
patients with an HLA-matched donor, but as with all bone 
marrow transplants, complications such as graft versus host 
disease (GVHD) may occur (Deiss, 1993).
Telomere shortening has been associated with progression 
to ANLL, an increase in cytogenetic abnormalities and a 
poor prognosis (Rosenfeld and List, 2000). Since telomeres 
are responsible for genomic stability, it is possible that 
the shortening of the telomeres, due to an increase in cell 
divisions (when the bone marrow is under stress) and 
complicated by advanced age (Jordan and Van Zant, 1998), 
may contribute to an increase in genomic instability and 
neoplastic progression (Marsh, 2000; Rosenfeld and List, 
2000).
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Collectively, the standing hypothesis regarding the 
evolution of AA to MDS is as follows: 1) initial injury to 
a progenitor cell occurs, possibly due to toxin exposure,
2) increased apoptosis of marrow cells (onset of AA) , 3) 
enhancement of telomere shortening resulting in genomic 
instability (development of early MDS), 4) a second insult 
to the cells, perhaps due to inactivation of a tumor 
suppressor gene, and lastly 5) progression to advanced MDS 
and ANLL (Barrett, et al., 2000; Rosenfeld and List, 2000).
Acute Nonlymphocytic Leukemia (ANLL)
ANLL is often referred to as acute myeloid leukemia 
(AML) ; however, ANLL is the more precise term and will 
therefore be used in this manuscript. ANLL is the 
culmination of disease progression that can start with the 
development AA followed by evolution to MDS and ending in 
ANLL. Environmental toxins, such as benzene, which 
contribute to the onset of AA and MDS also contribute to 
the onset of ANLL. In addition, ANLL may arise after 
chemotherapy, which damages the DNA. Chromosomal 
instability has been implicated in the development of ANLL, 
and cytogenetic abnormalities are common in most patients 
with ANLL (Greer et al., 1999; Greer and Kinney, 1993).
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ANLL is a clonal disorder that often presents with 
various cytopenias (neutropenia, thrombocytopenia) and the 
presence of blast cells (immature cells) in the bone 
marrow. Like MDS, the classification system for ANLL is 
poor and is based on phenotypic markers. ANLL has seven 
subcategories as defined by the FAB system: Ml, M2 and M3 
ANLL are mainly granulocytic, M4 ANLL shows >20% of the 
cells having monocytic origin, M5 ANLL shows >80% of the 
cells with a monocytic origin, M6 ANLL involves erythroid 
differentiation, and M7 ANLL is megakaryocytic (Greer et 
al., 1999; Greer and Kinney, 1993).
ANLL M2, M3 and M4 are associated with a good prognosis, 
and ANLL M5, M6 and M7 are associated with a poorer 
prognosis. Certain cytogenetic abnormalities are commonly 
seen in association with a particular subtype, such as 
t(8;21) with ANLL M2 and t(15;17) with ANLL M3. These 
translocations often involve known oncogenes and could 
result in their activation or the suppression of a tumor 
suppressor gene. Secondary ANLL is often associated with 
monosomy 7 or 5q-, which are considered to be indicators of 
a poor prognosis (Greer et al., 1999; Greer and Kinney, 
1993) . It is of interest to note that genes for five major 
cytokines are located in the 5q region (Deiss, 1993).
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As with other neoplasms, therapy involves chemotherapy or 
bone marrow transplantation. Chemotherapy involves a high 
dose of induction therapy, usually cytosine arabinoside 
combined with an anthracycline, followed by post-remission 
therapy. The cure rate using chemotherapy alone is between 
10-30%, while the cure rate with bone marrow 
transplantation is 45-65%. Patients with preceding MDS 
often have lower response rates to chemotherapy, and 
involvement of the central nervous system indicates a poor 
prognosis. Unfortunately, 40-80% of all patients will 
relapse, and 10-20% of patients with ANLL do not respond to 
any treatment (Greer et al., 1999; Greer and Kinney, 1993).
Aplastic Anemia (AA)
Background
AA is a bone marrow failure disorder that can progress to 
pre-leukemic conditions (MDS, etc.) and leukemia (Barrett 
et al., 200.0) . AA is characterized by the lack of 
precursor cell components for most cell types (Marsh, 2000; 
Young, 1999). Essentially, bone marrow production ceases; 
there is a reduction in red marrow (hematopoiesis) and an 
increase in yellow marrow (inactive fat cells) (Peterson, 
1995; Young, 1999; Young, 2000) (Figure 2). This condition 
is referred to as pancytopenia (Barrett et al., 2000; Lee,





(A) Normal bone marrow showing correct ratio between red 
and yellow marrow components. Photograph taken from
http : //www.vet .purdue. edu/vpb/clinpath/vpb555/lectlhematopoiesis/
(B) Bone marrow failure showing a decrease in red marrow 
and an increase in yellow marrow (Young, 1999)
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1999; On-line Medical Dictionary, 2001; Williams, 1993; 
Young, 2000). There are many different pathways that lead 
to the development of AA, causing difficulty in proper 
diagnosis and treatment for AA patients (Guinan, 1997). AA 
can occur from exposure to toxic chemicals such as benzene 
(via inhalation) Colby et al., 1996; Lee, 1999; Marsh and 
Geary, 1991; Young, 1999). Benzene can bind to DNA and 
RNA, creating adducts, which can degrade and contribute to 
DNA breakage (Shackelford et al., 1999). Radiation has 
also been linked to the development of AA through nuclear 
accidents or accidental exposures (Colby et al., 1996; 
Guinan, 1997; Lee, 1999; Marsh and Geary, 1991; Young,
2000). In addition, there are a wide variety of drugs that 
can induce AA, such as chloramphenicol (Colby et al., 1996; 
Guinan, 1997; Lee, 1999; Young, 1999; Young, 2000). Since 
there are no firm associations between drug dosages and the 
amount of time a drug was administered, it is hard to 
determine which drugs have a detrimental effect (Lee,
1999). Recently, AA has been associated with hepatitis 
patients, although a specific connection remains 
unidentified (Guinan, 1997; Lee, 1999; Young, 2000). AA 
may also be of familial origin, as in the case of Fanconi's 
anemia (FA) , an autosomal recessive disorder characterized 
by various abnormalities of the skeletal and urogenital
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systems, hyperpigmentation, and pancytopemia (Marsh and 
Geary, 1991; Russo and Zwerdling, 1992; ;Smith and Cox,
1999; Thurston et al., 1999) . However, 'the vast majority 
of AA cases are idiopathic (due to unknonm causes) (Colby 
et al., 1996; Lee, 1999; Online Medical Dictionary, 2001; 
Peterson, 1995; Storb, 1997; Young, 2000 ) .
Patients with AA present with one or imore of the 
following clinical characteristics: a Io t w  number of red 
blood cells (anemia) , a low number of wh.ite blood cells 
(leukopenia) and/or a low number of plat>elets 
(thrombocytopenia) (Lee, 1999; Online Me»dical Dictionary,
2001) . Due to the wide variety of abnormalities with 
symptoms and clinical findings similar t*o AA (PNH, MDS), 
diagnosis is often difficult (Lee, 1999; Young, 1999). 
Occasionally, cytogenetic abnormalities ^are present, which 
indicates a poor prognosis and a greater potential for 
disease progression to MDS or ANLL (Barr*ett et al., 2000; 
Kaito et al., 1998; La Starza et al., 19:98; Ohara et al., 
1997; Thurston et al., 1999) .
The majority of patients with AA have a normal karyotype 
analysis (Barrett et al., 2000). In patiients with severe 
aplastic anemia (SAA) (criteria established by the 
International Aplastic Anemia Study Groujp) , cytogenetic 
abnormalities usually include monosomy 7., trisomy 8 and/or
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trisomy 21 (Barrett et al., 2000; Colby, et al., 1996; La 
Starza et al., 1998; Ohara et al., 1997; Russo and 
Zwerdling, 1992; Thurston et al., 1999) . As with MDS, the 
presence of monosomy 7 is considered a poor prognosis 
(Thurston et al., 1999). The degree of severity of AA is 
diagnosed using the standards set forth by the 
International Agranulocytosis and Aplastic Anemia Study 
Group (Colby et al., 1996; Kaito et al., 1998; Lee, 1999).
It is estimated that 10% of patients with AA will develop 
PNH and 5-15% of patients with AA will progress to MDS or 
ANLL (Kaito et al., 1998; Ohara et al., 1997; Socie et al., 
2000; Tisdale, et al., 2000; Young, 1999). In those 
patients who progress to MDS, chromosomal abnormalities are 
frequently seen, and assist in the diagnosis of MDS 
(Barrett et al., 2000; Kaito et al., 1998; Ohara et al.,
1997; Socie et al., 1993; Young, 1999). Recent studies have 
linked the development of cytogenetic abnormalities such as 
monosomy 7 and trisomy 21 to previous treatment with G-CSF 
(Kaito et al., 1998; Ohara et al., 1997; Young, 1999).
This link has been noted in both children (Ohara et al., 
1997) and adults (Kaito et al., 1998) . G-CSF stimulates 
myelopoiesis and can assist in combating infection 
following immunosuppressive therapy (Frickhofen and 
Rosenfeld, 2000; Marsh, 2000; Sachs, 1996; Young, 1999).
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However, it is important that treatment with any cytokine 
be appropriately timed to ensure the destruction of all 
malignant cells (Sachs, 1996). It is theoretically 
possible that the treatment of patients, in the Ohara and 
Kaito studies, with both immunosuppressive therapy and G- 
CSF simultaneously may have resulted in protection of 
malignant cells from apoptosis followed by an expansion of 
the malignant cells. The common factor in all patients who 
exhibited complications, such as MDS or PNH, was treatment 
with G-CSF for over one year (Kaito et al., 1998; Marsh, 
2000).
A  recent study, of a patient with FA, using fluorescence 
in situ hybridization (FISH) , showed a higher percentage of 
cells with monosomy 7 than was recorded using conventional 
metaphase karyotype analysis. In addition, retrospective 
analysis indicated an increase in monosomy 7 levels over 
time (Thurston, et al., 1999). This and other studies show 
that FISH can detect chromosome abnormalities that are 
undetected by a karyotype analysis (Thurston et al., 1999; 
Socie et al., 2000; Young, 1999; Young, 2000). Such 
analysis is particularly useful in patients with AA, since 
routine karyotype analysis can be difficult because there 
is a lack of dividing cells (Barrett et al., 2000; De
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Planque et al., 1988; Socie et al., 2000; Tichelli et al., 
1988) .
Numerous recent reports support the hypothesis that 
acquired AA is an autoimmune disorder that is caused by 
attack on the hematopoietic system by lymphocytes (T-cells) 
(Colby et al., 1996; Tisdale, et al., 2000; Young, 1999; 
Young, 2000). Lymphocytes are recruited via cytokine 
signals (INF, IL2 and TNF), which leads to the activation 
of apoptosis via the Fas/Fas ligand pathway (Tisdale, et 
al., 2000; Young, 1999). INF-y and TNF-a levels are 
increased in patients with SAA, which can cause an increase 
in Fas-mediated apoptosis (Colby et al., 1996; Young,
2000). This autoimmune destruction may select for cells 
which are unaffected by autoimmune attacks such as PNH 
clones (see previous PNH section) or cells that are 
resistant to apoptosis (MDS), causing clonal expansion of 
those cells and the manifestation of the clinical disorders 
(Young, 1999; Young, 2000) (Figure 3).
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Autoimmune Destruction Clonal Escape
Figure 3. Hypothetical Pathway of Autoimmune Destruction
Stem cell insult occurs from drug exposure etc. (a viral 
infection is shown here), which causes a change in the 
production of the cell proteins and cell surface markers.
T cells are activated by a normal immune response to 
"foreign" cells and apoptosis occurs. Emergence of 
resistant clones results in clinical manifestations (Young,
1999) .
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Epidemiology
AA is primarily a disease of the young, with an average 
age of twenty-five (Young, 2000). In the United States and 
Europe, the incidence of AA is approximately 2 per million 
(Storb, 1997; Young, 1999; Young, 2000), while rates in the 
Far East are as high as 11 per million (Storb, 1997). AA 
is more common in developing nations perhaps owing to the 
lack of industrial standards and a higher rate of exposure 
to toxins such as benzene (Lee, 1999). AA is slightly more 
common in males (Barrett et al., 2000). However, in a 
study by Kaito et al. (1998), looking at the rate of 
transformation from AA to MDS, no statistical correlation 
was found with respect to the age of the patient, the sex 
of the patient, or the severity of the disease.
Treatment
Bone marrow transplant is the treatment of choice, except 
in cases where the age of the patient or lack of a suitable 
donor prohibits transplantation (Colby et al., 1996;
Guinan, 1997; Lee, 1999; Young 2000). Survival rates of up 
to 90% are achieved in young patients who undergo bone 
marrow transplantation prior to the increase of GVHD, which 
is found in patients over 30 years of age (Young, 2000). 
Whole body irradiation has decreased the rate of GVHD;
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future complications or death (Lee, 1999). Patients with 
no history of blood transfusions prior to bone marrow 
transplantation have a better chance of survival and 
remission (Colby et al., 1996; Guinan, 1997; Lee, 1999). 
Transfusions can increase the chance of graft rejection by 
causing an increased sensitivity to histocompatability 
antigens (Colby et al., 1996). The overall survival rate 
of patients undergoing bone marrow transplantation has 
continued to improve due to advances in technology (Guinan 
1997; Lee, 1999) .
In cases where bone marrow transplant is not an option, 
immunosuppressive therapy is the second choice (Frickhofen 
and Rosenfeld, 2000; Guinan, 1997; Lee, 1999; Young, 1999; 
Young, 2000). Treatment usually consists of ATG alone or 
in combination with cylosporin A (CsA) (Colby et al., 1996 
Guinan, 1997; Lee, 1999; Young, 1999; Young, 2000) . ATG 
works by inhibiting T cell mediated immune response, 
although the exact mechanism is unknown (Colby et al.,
1996; Frickhofen and Rosenfeld, 2000; Young, 2000) . CsA 
inhibits the transcription of several cytokines, blocking 
an immune response (Frickhofen and Rosenfeld, 2000). The 
rate of survival in patients who respond to 
immunosuppressive therapy can reach as high as 90% (Young,
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2000). The responsiveness of a patient is associated with 
the severity of the disease (Colby, et al-, 1996; Guinan, 
1997; Lee, 1999). G-CSF has been administered to some 
patients with AA, however treatment with G-CSF alone cannot 
induce remission (Young, 2000). G-CSF stimulates the 
myelopoiesis, and can aid in the effectiveness of other 
immunosuppressive drugs (Frickhofen and Rosenfeld, 2000; 
Guinan, 1997; Marsh, 2000; Young, 1999; Young, 2000). 
Unfortunately, immunosuppressive treatment has been 
associated with an increased risk of developing a 
hematological disorder, such as PNH, MDS or ANLL 
(Frickhofen and Rosenfeld, 2000; Lee, 1999; Marsh, 2000; 
Tisdale, et al., 2000; Young, 2000). Research is ongoing 
to establish a better therapy regimen that increases 
overall survival and remission rates while decreasing the 
risk of developing future complications (Guinan, 1997; Lee, 
1999).
Alternate therapies to ATG and CsA are being investigated 
such as cyclophosphamide, a potent immunosuppressive drug 
(Frickhofen and Rosenfeld, 2000; Tisdale, et al., 2000; 
Young, 1999; Young, 200 0). Preliminary data shows that 
patients treated with cyclophosphamide do not develop 
clonal disorders (PNH or MDS) and do not relapse (Tisdale, 
et al., 2000; Young, 1999).
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In addition to immunosuppressive therapy, supportive 
care, such as regular blood transfusions, is part of the 
treatment regimen (Lee, 1999; Young, 2000). However, 
caution should be used when the patient is eligible for a 
bone marrow transplant, since patients who have not had any 
prior blood transfusions have a greater successful response 
rate to bone marrow transplantation (Lee, 1999). Another 
key to successful treatment that is often overlooked, is 
prevention of infection, which can only compound problems 
within an already reduced immune system (Lee, 1999).
CELL CYCLE
General Overview
By definition, the cell cycle is "the sequence of events 
between mitotic divisions" (Online Medical Dictionary,
2001) . The end result from one round of cell division is 
two genetically identical daughter cells (Johnson and 
Walker, 1999). The cell cycle includes interphase 
(comprised of Gl, S and G2) and mitosis (Figure 4) . Cells 
that are quiescent are in GO, a non-dividing cell resting 
state (Jacks and Weinberg, 1998; Johnson and Walker, 1999; 
Shackelford et al., 1999).
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Figure 4. The Cell Cycle 
Photograph taken from
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During Gl, the cell synthesizes RNA and proteins in 
preparation for DNA replication (Hagan et al., 1999;
Johnson and Walker, 1999) . G1 is the longest stage (in
animals), comprising nearly half of the total cell cycle
time (Shackelford et al., 1999). During the S phase, the 
DNA is replicated, and upon completion, the cell now 
contains two copies of the same DNA (Hagan et al., 1999;
Johnson and Walker, 1999). S phase comprises almost one
quarter of the entire cell cycle time (Shackelford et al., 
1999). During G2, the cell prepares to enter mitosis 
(Hagan et al., 1999; Johnson and Walker, 1999). G2 phase 
comprises less than one quarter of the total cell cycle 
time. G2 is followed by mitosis, which is the shortest 
part of the cell cycle. The cell cycle repeats every 18-24 
hours (Shackelford et al., 1999).
Mitosis is broken down into four substages: prophase, 
metaphase, anaphase and telophase. During prophase, the 
mitotic spindle begins to form in the cytoplasm. The 
chromatin condenses, forming the X-shaped chromosomes, and 
the centrosomes, comprised of two centrioles, begin to move 
apart. In preparation for metaphase, the nuclear envelope 
disintegrates, and the centrosomes localize to the spindle 
poles on opposite sides of the cell. The spindle fibers, 
comprised of microtubules, attach to the kinetochores,
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which are located in. the centromeric region of each 
chromosome (Willard, 2000) . In metaphase, the chromosomes 
attach to the spindle apparatus as they begin to align 
along the metaphase plate in between the two spindle poles. 
During anaphase, the sister chromatids divide and move 
toward opposite poles with help from the spindle apparatus 
attached to the kinetochore region. During the final phase 
of mitosis, telophase, the nuclear envelopes begin to 
reform, with one envelope surrounding each set of 
chromosomes. The chromatin begins to uncoil, and the 
cytoplasm divides (cytokinesis) (Campbell, 1993).
Mitotic Cell Cycle Checkpoint Mechanisms
Many cell cycle controls (checkpoints) are built into the 
cell cycle to ensure correct cell division (Johnson and 
Walker, 1999; Shackelford et al., 1999). Cell cycle 
checkpoints are mediated by the activity of cyclin/cdk 
(cyclin-dependent kinase) complexes (Hagan et al., 1999; 
Shackelford et al., 1999). During interphase, there are 
two main checkpoints. The first checkpoint is a 
restriction point located prior to the S phase (Hartwell 
and Kastan, 1994; Johnson and Walker, 1999; Shackelford et 
al., 1999) (Figure 4 and Figure 5). Here, the cell must 
decide whether to continue in the cell cycle or abort and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
30
C vc lin  B 
v  cdk2 >
A ntipro liferative 
signals
•̂ Cvclin D 
cdk4/cdk<
C vc lin  A  
v  cdk2 >
MitogensC vclin  E  
v. cdk2 ^C vc lin  A  
v  cdk2 >
Restriction Point
pRB Phosphorylation
Figure 5. Cyclin/cdk Complexes Within the Cell Cycle
Pictorial representation of the Cyclin/cdk protein 
complexes and their locations within the cell cycle control 
(Shackelford et al., 1999).
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enter the GO quiescent stage (Johnson and Walker, 1999). 
Once the cell has decided to continue with the cell cycle, 
there is no turning back (Johnson and Walker, 1999; 
Shackelford et al., 1999). The G1 checkpoint ensures that 
damaged DNA is not replicated (Hartwell and Kastan, 1994) . 
The second checkpoint occurs in late G2, prior to entering 
mitosis (Johnson and Walker, 1999; Shackelford et al.,
1999). This checkpoint is controlled by the levels of 
maturation (or M phase) promoting factor (MPF), and ensures 
that DNA replication is complete prior to the initiation of 
mitosis (Hartwell and Kastan, 1994; Shackelford et al., 
1999).
D-type cyclins induce the division of GO cells. The 
levels of D-type cyclins remain constant throughout the 
cell cycle (Johnson and Walker, 1999). D-type cyclin 
kinases phosphorylate the retinoblastoma tumor suppressor 
protein (Rb), which is involved in the restriction point 
during G1 (Figure 5) (Bartek et al., 1999; Johnson and 
Walker, 1999; Shackelford et al., 1999). After 
phosphorylation, the Rb protein dissociates from E2F, a 
transcription factor that regulates the expression of 
cyclin E. The formation of a cyclin E/cdk2 complex is 
required for the transition into S phase (Figure 5).
Cyclin A negatively regulates E2F (Johnson and Walker,
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1999; Shackelford et al., 1999). Entry into mitosis is 
controlled by MPF, which is controlled by the level of 
cyclin B (Hagan et al., 1999; Shackelford et al., 1999). 
Cyclin B binds to p34cdc2 (cell division cycle 2), a cdk that 
is part of the MPF (Figure 5) (Shackelford et al., 1999). 
Upon binding to cyclin B, and after phosphorylation, p3 4cdc2 
becomes active. When p34cdc2 is active, it will activate the 
MPF, phosphorylate many cell cycle components, and initiate 
the formation of the mitotic spindle (Hagan et al., 1999; 
Shackelford et al., 1999). During mitosis, cyclins A, B1 
and B2 associate with cdkl, and are responsible for 
phosphorylation of a wide variety of targets including 
components of the mitotic spindle (Johnson and Walker,
1999; Shackelford et al., 1999). Mitosis is completed when
the destruction of cyclin B inhibits MPF function (Hagan et 
al., 1999). Once the cell has completed mitosis, the 
process begins anew with cyclin building up until it 
reaches the threshold level required to initiate cell 
division (Hagan et al., 1999; Johnson and Walker, 1999).
Cyclin-dependent kinase inhibitors (OKI) regulate the 
cyclin/cdk complexes (Johnson and Walker, 1999) . One 
member of this family is p21, which is activated by p53, 
and (when active) is responsible for the inhibition of the 
cell cycle. Activation of p21 halts DNA replication to
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allow for repair of damaged DNA (Johnson and Walker, 1999; 
Shackelford et al., 1999). Therefore, certain cancers that 
have altered p53 function may be unable to activate p21, 
which would allow damaged DNA to undergo replication. 
Mutations in p53 are common in cancer, which leads to an 
increase in genomic instability manifested by a high level 
of chromosomal abnormalities (Johnson and Walker, 1999) . 
Another CKI, pl6, is known to inhibit Rb phosphorylation 
(Johnson and Walker, 1999; Shackelford et al., 1999). When 
Rb phosphorylation is inhibited, E2F is not activated and 
the cell cannot undergo DNA replication.
During metaphase, the chromosomes align along the 
metaphase plate prior to their separation during anaphase. 
Separation of chromosomes is assisted by microtubules in 
the mitotic spindle that are attached to one of the two 
microtubule organizing centers (MTOCs) located at the 
spindle poles. Movement of the chromosomes is accomplished 
by microtubule motor proteins (Hagan et al., 1999) . The 
mitotic spindle checkpoint ensures that all chromosomes are 
aligned properly and attached to the spindle apparatus 
before division occurs (Davenport et al., 1999; Elledge, 
1998; Hwang et al., 1998; Imai et al., 1999; Nicklas, 1997; 
Paulovich et al., 1997). The mitotic spindle checkpoint is 
comprised of genes from the MAD (mitotic arrest deficient)
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and BUB (budding uninhibited by benzimidazole) families and 
is discussed in further detail below (Shackelford et al., 
1999). A defect in the mitotic spindle checkpoint would 
allow premature anaphase and may lead to uneven chromosome 
division.
BUB and MAD Gene Families
In the yeast Saccharomyces cerevisiae, there are seven 
genes identified (to date) which are required for the 
spindle assembly checkpoint. These include BUB genes 2, 2 
and 3, MAD genes I, 2 and 3, and MPS1, (monopolar spindle 
1) a protein kinase (Basu, et al., 1999; Bernard et al., 
1998; Hardwick, et al., 1996; Jin et al., 1998; Pangilinan 
et al., 1997) . Mammalian homologues of BUB1, BUB3, MAD1, 
MAD2 and MAD3 (which is occasionally referred to as BUBR1, 
due to similarities to both the BUB and MAD gene families) 
localize during prometaphase to the kinetochore region of 
chromosomes that are not attached to the spindle apparatus, 
and disappear once stable attachment is achieved during 
metaphase (Elledge, 1998; Fraschini et al., 1999; Hardwick 
et al., 2000; Li and Benezra, 1996; Li, 1999). However, 
BUB2 localizes to the spindle poles, indicating a 
potentially different function from BUB1, BUB3, MAD1 and 
MAD2 (Fraschini et al., 1999; Hardwick et al., 2000; Li,
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1999) . Many hypothesize that BUB1, BUB3 and MAD1-3 
proteins all form a complex that targets unattached 
kinetochores, comprising the mitotic spindle checkpoint 
(Fraschini et al., 1999; Li, 1999; Seeley et al., 1999).
It is also hypothesized that BUB2 assists in the regulation 
of cytokinesis (Fraschini et al., 1999; Li, 1999).
Evidence supporting this theory is found in fission yeast 
where cdcl6, the fission yeast homologue of BUB2, 
negatively regulates cytokinesis, and is localized to the 
spindle poles (Fraschini et al., 1999; Li, 1999). The 
kinetochore-binding domain CENP-E has also been implicated 
in the mitotic spindle checkpoint (Chan et al., 1998).
Like the other checkpoint proteins, CENP-E localizes to the 
kinetochore (Chan et al., 1998). CENP-E is a motor-kinase 
and is thought to contribute in the shortening of the 
spindle apparatus during metaphase (Chan et al., 1998) .
There is evidence that BUB1, BUB3 and MAD1-3 proteins all 
interact (Figure 6). BUB1 undergoes autophosphorylation 
and also phosphorylates BUB3 (Farr and Hoyt, 1998;
Hardwick, 1998; Martinez-Exposito et al., 1999; Roberts et 
al., 1994; Taylor and McKeon, 1997). In addition, the 
binding of BUB3 to BUB1 is necessary for kinetochore 
localization of BUB1 (Fraschini et al., 1999; Seeley et 
al., 1999; Taylor et al., 1998). MAD3 (BUBR1) binds to












Figure 6. Hypothesized Interaction of the BUB/MAD 
Proteins, and Their Possible Role in the Regulation of the 
Mitotic Spindle Checkpoint.
BUB1 binds to BUB3, which is necessary for kinetochore 
localization of BUB1. BUB3 is phosphorylated by BUB1 and 
BUB1 is autophosphorylated. The BUB1/BUB3 complex binds to 
MAD1, and MAD1 is phosphorylated by MPS1. From there, it 
is hypothesized that MAD2 and MAD3 (BUBR1) are added to the 
complex. By an unknown mechanism, the newly formed complex 
inhibits CDC20 which prevents activation of the APC. By 
inhibiting the activation of the APC, anaphase is blocked.
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BUB3, (Hardwick et al-, 2000; Taylor et al., 1998) and MAD1 
binds to BUB1 (Seeley et al., 1999). MAD 1-3 interact with 
each other and with the anaphase promoting complex (AJ?C) in 
yeast, and MAD2 is able to inactivate CDC20 and stabilize 
Pdsl (in S. cerevisiae) and cyclin B. This blocks the 
onset of anaphase by preventing the destruction of Pdsl and 
cyclin B (Elledge, 1998; Hardwick et al., 2000; Hwang et 
al., 1998; Li and Benezra, 1996; Taylor et al., 1998).
MAD1 binds to MAD2, and MAD1 is phosphorylated by MPS1 
(Bernard et al., 1998; Farr and Hoyt, 1998; Fraschini et 
al., 1999; Taylor and McKeon, 1997; Taylor et al., 1998).
CENP-E has been shown to colocalize and bind to MAD3 




The human BUB1 protein is a 1,021 amino acid (aa), 188- 
kDa protein which contains three main functional domains: 
CD1, which is highly conserved and directs kinetochore 
localization, NLS, a nuclear localization signal sequence 
and CD2, a highly conserved carboxy-terminal serine- 
threonine-like protein kinase domain (Cahill et al., 1999;
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Pangilinan et al., 1997; Roberts et al., 1994). Both 
kinetochore localization (the BUB1 protein must be near the 
kinetochore region to facilitate in the binding of the
mitotic spindle to the kinetochore) and nuclear
localization (the BUB1 protein must be within the nucleus 
of the cell to be able to localize to the kinetochore) of 
hBUBl are essential to the function of hBUBl. hBUBl is a 
protein kinase with 25 exons located on chromosome 2ql2-ql4 
(Cahill et al., 1999; Pangilinan et al., 1997; Roberts et 
al., 1994) . Exons 2-5 (codons 21-152) encode for the CD1 
region, while exons 8 and 9 (codons 207-319) encode for the 
NLS region, and exons 20-25 (codons 732-1043) encode for 
the CD2 region. A hBUB3 binding site is located between
CD1 and CD2 in the presumptive NLS area (Cahill et al,
1998; Cahill et al., 1999). Cahill et al. found that two 
of 19 colorectal cancer cell lines had mutations within 
hBUBl, and also showed high levels of aneuploidy (Cahill et 
al., 1998).
BUB1 homologues have also been found in a variety of 
organisms, including mice (Taylor and McKeon, 1997), 
Drosophila (Basu et al., 1999), fission yeast 
Schizosaccharomyces pomhe (Bernard et al., 1998) and 
Aspergillus nidulans (Efimov and Morris, 1998). Bernard et 
al. showed that in S. pomhe, BUB1 was also localized to the
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kinetochore region upon activation of the spindle 
checkpoint. In addition, loss of the BUB1 gene in S. pombe 
instigated chromosomal segregation defects, from failure of 
sister chromatid segregation, producing a higher aneuploidy 
rate, and an increase in lagging chromosomes in late 
anaphase (Bernard et al., 1998). Taylor and McKeon showed 
that when the function of the murine homologue of BUB1 is 
abrogated (a suppressed mitotic spindle checkpoint), cells 
successfully avoid apoptosis and continue in the cell cycle 
(Taylor and McKeon, 1997). Basu et al. found that in 
Drosophila, severe mutations of BUB1 (missgregation and 
fragmentation) were responsible for elevated levels of 
chromosome abnormalities, and ultimately death of the 
Drosophila larvae (Basu et al., 1999). In contrast to 
Taylor and McKeon's findings (above, Taylor and McKeon,
1997), severe mutations of BUB1 in Drosophila induced a 
higher apoptotic state (Basu et al., 1999). The study of 
BUB1 in Drosophila is the first study to assess BUB1 in a 
multicellular organism (Basu et al., 1999).
GENOMIC INSTABILITY AND CANCER
The hallmark of cancer is an uncontrolled cell cycle 
(Bartek et al., 1999; Hartwell and Kastan, 1994; Johnson
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and Walker, 1999). The accumulation of mutations may lead 
to cancer (Imai et al., 1999: Ohshima et al., 2000; Orr- 
Weaver and Weinberg, 1998). Many hypothesize that genetic 
instability leads to an increase in the mutation rate and 
the onset of cancer (Boland and Ricciardiello, 1999; Cahill 
et al., 1998; Hartwell and Kastan, 1994; Imai et al., 1999; 
Jaffrey et al., 2000; Lengauer et al., 1997; Myrie et al., 
2000; Ohshima et al., 2000). There are two forms of 
genetic instability: chromosomal instability (CIN) and 
microsatellite instability (MIN) (Cahill et al., 1999; Imai 
et al., 1999; Jaffrey et al., 2000) .
Chromosomal Instability
CIN is characterized by malsegregation of chromosomes and 
presents as aneuploidy at the chromosomal level (Bernard et 
al., 1998; Cahill et al., 1998; Cahill et al., 1999; Imai 
et al, 1999; Jaffrey et al., 2000; Lengauer, et al., 1997; 
Myrie et al., 2000; Orr-Weaver and Weinberg, 1998). 
Aneuploidy and other chromosomal aberrations are frequently 
associated with a variety of cancers and tumors (Boland and 
Ricciardiello, 1999; Davenport et al., 1999; Hartwell and 
Kastan, 1994; Imai et al., 1999; Lengauer et al., 1997; 
Myrie et al., 2000; Yamaguchi et al., 1999).
Theoretically, aneuploidy may occur as a direct result of
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an aberrant mitotic spindle checkpoint (Bernard et al., 
1998; Cahill et al., 1998; Cahill et al., 1999; Jaffrey et 
al., 2000; Ohshima et al., 2000; Orr-Weaver and Weinberg,
1998). Cells that proceed to anaphase before all 
chromosomes are aligned along the metaphase plate may 
result in a gain or loss of chromosomes. Monosomy 7 and 
other abnormalities have been observed in patients with AA, 
MDS and ANLL (Barrett et al., 2000; De Planque et al.,
1988; Kaito et al., 1998; Ohara et al., 1997; Socie et al.,
2000), and monosomy 7 is associated with a poor prognosis 
(Greer, et al., 1999).
Microsatellite Instability
MIN is characterized by mutations in mismatch repair 
genes, and results in mutations at the nucleotide level 
(Boland and Ricciardiello, 1999; Cahill et al., 1998;
Cahill et al., 1999; Lengauer et al., 1997; Orr-Weaver and 
Weinberg, 1998). Tumors with MIN usually contain the 
correct number of chromosomes and do not exhibit aneuploidy 
(Orr-Weaver and Weinberg, 1998). However, nucleotide 
mutations may occur in oncogenes and tumor suppressor 
genes, leading to the inactivation of tumor suppressor 
genes or the activation of oncogenes (Cahill et al., 1999).
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HYPOTEHSIS AND RESEARCH AIMS
In this study, I hypothesized that mutations or base pair 
changes within the mitotic spindle checkpoint gene hBUBl 
directly correlated with the presence of aneuploidy in 
patients with bone marrow failure disorders. To test this 
hypothesis, two specific aims were addressed.
Recent experiments have shown that the emergence of 
abnormal clones in patients with AA coincides with a 
transformation to MDS (De Planque et al., 1988; Socie et 
al., 2000). In addition, as the disease progresses, more 
cytogenetic abnormalities occur (Socie et al., 2000). At 
present, karyotype analysis is used to evaluate the 
cytogenetic makeup of a patient. However, in patients with 
AA, this is often hard to accomplish because of the low 
number of metaphase cells present (Barrett et al., 2000; De 
Planque et al., 1988; Socie et al., 2000; Tichelli et al., 
1988). Some researchers have shown that cytogenetic 
analysis by FISH is more sensitive than karyotype analysis 
(Thurston et al., 1999; Socie et al., 2000; Young, 1999;
Young, 2000). In addition, FISH can be performed on 
patients with AA, since the procedure is primarily 
performed on interphase nuclei and does not rely on the 
existance of metaphase cells. Perhaps FISH analysis can
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detect early clonal abnormalities normally missed with, 
karyotype analysis, and provide a "warning sign", 
indicating a potential transformation to MDS. Early clonal 
changes have been detected by karyotype in patients prior 
to transformation to MDS or ANLL (Marsh and Geary, 1991; 
Socie et al., 2000). In addition, a Seattle study showed 
that a greater percentage of AA patients with an abnormal 
karyotype underwent transformation to MDS or ANLL, while 
very few AA patients with a normal karyotype progressed to 
MDS or ANLL (Socie et al., 2000) . Marsh and Geary have 
concluded that "an acquired clonal cytogenetic marker in a 
patient with otherwise typical AA represents a pre- 
leukaemic state" (Marsh and Geary, 1991). Therefore, my 
first specific aim was to compare conventional karyotype 
analyses with FISH analyses in samples from patients with 
AA. Initial cytogenetic testing using FISH analysis may 
complement a karyotype analysis, and could assist in a more 
complete and earlier diagnosis and guide correct 
preventative treatment in patients with AA. Patients with 
MDS and ANLL commonly present with either monosomy 7 or 
trisomy 8, of which, monosomy 7 is considered a poor 
prognosis (Socie et al., 2000). Therefore, FISH was 
performed for chromosomes 7 and 8.
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Secondly, aneuploidy is common in many cancers, and may 
be caused by a variety of things, such as structural 
defects in centrosomes or the mitotic apparatus, or defects 
in cell cycle control (Bartek et al., 1999; Pihan et al., 
1998; Saunders et al., 2000). Some cancerous cell lines
contained abnormal centrosomes and showed high levels of 
CIN and aneuploidy that were not seen in normal cell lines 
(Pihan et al., 1998). Other cancerous cell lines were 
shown to have multipolar spindles, perhaps due to a defect 
in the MTOCs (Saunders et al., 2000).
Theoretically, aneuploidy may also be caused from an 
aberrant mitotic spindle checkpoint. When the mitotic 
spindle checkpoint is viewed as a complex, one can assume 
that dysfunction in any of the components may compromise 
the function of the checkpoint. hBUBl is the most 
characterized of the mitotic spindle checkpoint genes, and 
was mutated within two colorectal cancer cell lines (Cahill 
et al., 1998). Therefore, as my second specific aim, I 
chose to look for the presence of mutations or base pair 
changes within hBUBl in samples from patients with AA.
Since some mutations in hBUBl have a dominant negative 
effect (Cahill et al., 1998), any mutation that alters the 
function of BUB1 could potentially alter the mitotic 
spindle checkpoint. Should this be the case, one might
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predict to find a high level of aneuploidy in patients 
having a mutation in the hBUBl gene. Therefore, the same 
subset of patients underwent both FISH analysis and 
sequencing of the hBUBl gene functional domains shown to be 
required for kinetochore and nuclear localization (CD1 and 
NLS) (Cahill et al., 1999; Pangilinan et al., 1997; Roberts 
et al., 1994).





The National Institutes of Health, Heart, Lung and Blood 
Division in Bethesda, Maryland kindly provided patient 
samples consisting of whole bone marrow. The institutional 
review board authorized the use of human samples (IRB# 
1303000246E)
SOLUTIONS
Below is a listing of solutions used in this study and 
their corresponding formulas:
• 2X SSC: Combined 100ml 20X SSC, pH 7.0 with 900ml water.
• 20X SSC, pH 7.0; 3M sodium chloride, 0.3M sodium citrate: 
Combined 175.3g sodium chloride (Sigma) and 88.2g sodium 
citrate (Sigma) in 800ml water. The pH was adjusted to
7.0 and water was added to a final volume of 1L.
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• 4X SSC/0.05% Tween 20, pH 7.0: Combined 200ml 20X SSC, pH
7.0 with 0.5ml Tween 20 (Fisher) and added water to at 
final volume of 1L.
• 4X SSC/0.05% Tween 20/0.05% blocker: Combined 200ml 2:0X 
SSC, pH 7.0 with 0.5ml Tween 20 and 0.5g blocker 
(Boehringer Mannheim) . Water was added to a final vo»lume 
of 1L.
• 50% formamide/2X SSC, pH 7.0: Combined 50ml formamide: 
(Fisher), 10ml 20X SSC, pH 7.0 and 40ml water to a fi_nal 
volume of 100ml.
• 60% formamde/2X SSC/10% dextran sulfate: Combined 6nfL 
formamide, 1ml 20X SSC, pH 7.0 and lg dextran sulfate: - 
Water was added to a final volume of 10ml. Solution was 
stored at -7 0°C until use.
• 70% formamide/2X SSC: Combined 70ml formamide, 10ml 2:OX 
SSC, pH 7.0 and 20ml water to a final volume of 100ml..
• DAPI, stock (lOmg/ml) : Dissolved lOmg DAPI (Sigma) in_ 1ml 
phosphate buffered saline (PBS).
• Ethidium Bromide, stock (lOmg/ml): Dissolved lg ethidiium 
bromide (Sigma) in 100ml water. Solution was stored in 
the dark.
• Fixative: Combined 75ml methanol (Fisher) and 25ml 
glacial acetic acid (Fisher) for a final volume of 10‘0ml.
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• Lennox broth (LB) agar plates: Combined lOg tryptone 
(Difco), 5g yeast extract (Difco) , 5g sodium chloride, 
lml IN sodium hydroxide (Fisher) and 15g agar (Difco) 
with water added to a final volume of 1L. Autoclaved. 
Cooled solution to 50°C and added the following 
antibiotics: lml ampicillin (50mg/ml) (Sigma), lml IPTG 
(lOOmM) (Sigma) , and lml X-gal (20mg/ml) (Sigma) . 15ml 
of the solution was aliquoted into a sterile 100mm petri 
dish and allowed to dry in a laminar flow hood for 30 
minutes. Plates were stored at 4°C until use.
• LB media: Combined lOg tryptone, 5g yeast extract, 5g 
sodium chloride and lml IN sodium hydroxide with water 
added to a final volume of 1L. Autoclaved. LB media was 
stored at 4°C until use.
• Phosphate buffered saline (PBS), Ix, pH 7.4; 0.14M sodium 
chloride, 0.003M potassium chloride, 0.01M sodium 
phosphate, dibasic, 0.002M potassium phosphate, 
monobasic: Combined 8g sodium chloride, 0.2g potassium 
chloride (Fisher), 1.44g sodium phosphate, dibasic 
(Fisher) and 0.24g potassium phosphate, monobasic 
(Fisher) in 800ml water. The pH was adjusted to 7.4 and 
water was added to a final volume of 1L. The solution 
was autoclaved.
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• Potassium chloride, 0.075M solution: Dissolved 2.8g 
potassium chloride in 500ml water.
• Tris-EDTA (TE) buffer, pH 7.4; 0.0007M Tris-Cl, 0.001M 
EDTA: Combined 0.112g Tris-Cl (Sigma) and 0.372g disodium 
thylenediamine tetraacetate (EDTA) (Fisher). Water was 
added to a final volume of 500ml.
HARVEST OF BONE MARROW CELLS
The bone marrow samples were harvested upon receipt using 
the following protocol: 0.075M KC1 was warmed to 37°C while
0.5ml bone marrow sample was aliquoted into a labeled 15ml 
centrifuge tube. The cells were vortexed while adding 
warmed 0.075M KC1 to a total volume of 5ml, followed by a 
10 minute incubation in a 37°C water bath. While the cells 
were incubating, fresh fixative was prepared (see 
solutions). The cells were centrifuged at 1000 rpm for 5 
minutes, and the supernatant was discarded to just above 
the white band of cells. The cells were vortexed while 5ml 
of fresh fixative was added dropwise, then the cells were 
re-centrifuged at 1000 rpm for 5 minutes. The addition of 
fixative followed by centrifugation was repeated twice. 
Again the cells were vortexed while 5ml of fresh fixative
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was added dropwise, and the cells were stored in fixative 
at -20°C until further use.
LABELING OF FISH DNA PROBES
In this study, a pre-mixed nick translation mix by 
Boehringer Mannheim was used according to the 
manufacturer's protocol. Briefly, dATP, dCTP, dGTP, dTTP, 
molecular biology grade (MBG) water (5 prime-^3 prime), and 
a fluorescent label (see below) were combined to form the 
"5X fluorophore-labeling mix". Nick translation mix, 
template DNA and MBG water were added to the 5X 
fluorophore-labeling mix. The sample was incubated for 90 
minutes at 15°C followed by a 10-minute incubation at 65°C. 
The samples were stored at -20°C until use.
Two-probe, two-color FISH was performed on chromosomes 7 
and 8 simultaneously. Chromosome 7 was labeled with 
Biotin-16-dUTP (biotin-16-2' -deoxyuridine-5'-triphosphate) 
(Boehringer Mannheim) and detected with NeutrAvidin- 
fluorescein (Molecular Probes). Chromosome 8 was labeled 
with DIG-ll-dUTP (digoxigenin-11-2'-deoxy-uridine-5'- 
triphosphate) (Boehringer Mannheim) and detected with anti- 
DIG rhodamine (Boehringer Mannheim) .
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FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
Slides were prepared as follows: the fixed cells were 
centrifuged at 1000 rpm for 5 minutes, and the supernatant 
was discarded. Fresh fixative was prepared (see 
solutions), and while vortexing the cells, the fixative was 
added until a milky color was obtained. Slides were 
cleaned with ethanol (Fisher) and dried with a KimWipe 
(Kimberly Clark). Twenty microliters of the cell 
suspension was dropped onto each slide and allowed to air 
dry. The slides were stored at -70°C until use.
The FISH procedure was continued as follows: slides were 
first brought to room temperature. Then, the cells were 
incubated for 3 minutes in 70% formamide/2X SSC, pH 7.0 at 
70-75°C to denature the DNA. The cells were washed in cold 
50% ethanol, cold 70% ethanol and cold 95-100% ethanol, 
each for two minutes. While the cells were being washed, 
the probe mix was prepared by combining the following:
Labeled probe lp.1 of each
Hybridization Buffer (60% formamide/
2X SSC/10% dextran sulfate) 7pl
MBG water lp.1
The probe mix was denatured for 5 minutes at 8 0°C on a hot 
block and placed on ice. Slides were removed from the
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ethanol and air-dried. Ten microliters of the probe mix 
was placed on each slide; the slide was covered with a 
22x22mm glass cover slip and sealed with rubber cement 
(Ross) . Hybridization followed for 2-24 hours in a 37°C 
incubator.
Upon completion of hybridization, stringency washes were 
performed on the cells using the following procedure: three 
washes of fresh 50% formamide/2X SSC, pH 7.0, each for 5 
minutes at 42°C, followed by one wash in 2X SSC, pH 7.0 for 
5 minutes at 42°C, followed by one wash in 4X SSC/0.05% 
Tween 20, pH 7.0 for 5 minutes at 42°C and ending with one 
wash in 4X SSC/0.05% Tween 20, pH 7.0 for 5 minutes at room 
temperature. The cells were incubated in a solution of 4X 
SSC/0.05% Tween 20/0.05% blocker for 20 minutes at room 
temperature. While incubating, the conjugate mixes were 
prepared as follows:
Anti-DIG: 10pl anti-digoxygenin rhodamine,
(200ug/ml) (Boehringer Mannheim) 
490pl 4X SSC/0.05% Tween 20/0.05% 
blocker
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Avidin-FITC: lpl fluorescent NeutrAvidin-FITC
conjugate, (lmg/ml) (Molecular 
Probes)
499y.l 4X SSC/0.05% Tween 20/0.05% 
blocker
Conjugate mixes were centrifuged for 5 minutes at 12,000 x 
g, and the supernatant was collected. Then, 10pl of each 
conjugate mix was added to the cells, the cells were 
covered with Parafilm M (American National Can) and 
incubated for 30 minutes in a dark, moist chamber at 37°C. 
Finally, the cells were washed in three washes of fresh 4X 
SSC/0.05% Tween 20, each for 5 minutes at room temperature. 
Once washing was complete, the slides were removed and 
excess fluid was drained. Ten microliters of diluted DAPI 
(4', 6-diamidino-2-phenylindole) was applied to the slide, 
the cells were covered with a 22x22mm glass cover slip, and 
viewed using a Nikon fluorescent microscope with cooled CCD 
camera.
CALCULATION OF THE MITOTIC INDEX (MI)
% MI = (# cells in metaphase / total # of cells)*100
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ISOLATION OF RNA FROM BONE MARROW
The TRIZOL® procedure from Life Technologies was used in 
this study according to the manufacturer's directions. In 
brief, 0.5ml bone marrow sample was placed into a 
microcentrifuge tube. The cells were centrifuged and the 
supernatant was discarded. TRIZOL® Reagent was added 
followed by a brief incubation at room temperature. Then, 
chloroform (Fisher) was added and the sample was again 
incubated at room temperature, followed by centrifugation 
to separate the sample into distinct layers. The upper 
aqueous layer was recovered, and isopropyl alcohol (Fisher) 
was added to precipitate the RNA. The sample was briefly 
held at room temperature, followed by centrifugation. The 
supernatant was discarded and the RNA pellet was dried, and 
then re-dissolved in MBG water. The optical density, at 
260nm, of the dissolved RNA was recorded using a 
spectrophotometer, and the RNA concentration was calculated 
from the relationship that 40p.g/ml RNA = 1.00 OD2 6 0.
REVERSE TRANSCRIPTION OF RNA
The commercially available reverse transcription system 
from Promega was used during this study according to the
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manufacturer's instructions. Briefly, MBG water, magnesium 
chloride, RT 10X Buffer, dNTP mixture, Recombinant RNasin® 
Ribonuclease Inhibitor, AMV Reverse Transcriptase,
Oligo (dT) 15 Primer, and l.Opg of total RNA were combined. 
The sample was incubated at 42°C for 30 minutes, followed 
by a 5-minute incubation at 99°C, and another 5-minute 
incubation on ice. The newly synthesized cDNA was stored 
at -20°C until further use.
POLYMERASE CHAIN REACTION (PCR)
A  set of two primers (Gibco BRL) were used to amplify the 
first 1214 base pairs of the hBUBl coding region. This 
area included the CD1 region and the NLS region. The 
primer set used was (Cahill, personal communication):
Primer 1 Forward 5' -CATGGACACCCCGGAAAATGTC-3'
Primer 2 Reverse 5' -GCATCTTTGCTGGCCACTGC-3'
Primer 1 was located at base pairs 4 9 through 70, and 
primer 2 was located at base pairs 1244 through 1263 in the 
consensus hBUBl sequence. PCR was accomplished using the 
Epicentre MasterAmp™ Taq DNA Polymerase and the following 
protocol, in brief, according to the manufacturer's 
instructions. MBG water, 10X PCR Buffer, magnesium 
chloride, dNTP, forward PCR primer, reverse PCR primer, Taq
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DNA Polymerase, and the cDNA template were combined in a 
PCR reaction tube. Seventy microliters of mineral oil was 
added to each PCR reaction tube, and the PCR reaction was 
completed using the following program specific for hBUBl 
PCR:
1. 95°C for 1 minute
2. 95°C for 30 seconds
3. 56°C for 30 seconds
4. 70°C for 2 minutes
5. Repeat to step 2, 35 times
6. 70°C for 5 minutes
7. Hold at 4°C
PCR results were viewed on a 1% agarose (Sigma) gel in IX 
TBE (Tris-borate EDTA) stained with diluted ethidium 
bromide.
ISOLATION OF DNA FROM AN AGAROSE GEL
The Geneclean kit from BIO101 was used with the following 
protocol according to the manufacturer's directions. In 
brief, the PCR products were electrophoresed on a 1% 
agarose gel in IX TAE (Tris-Acetate-EDTA), excised from the 
gel and weighed. 6M Sodium Iodide (Nal) was added, and the 
gel/Nal mixture was incubated in a 55°C water bath until
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the gel was completely dissolved. Glassmilk (BIO101) was 
added to each tube and the samples were vortexed, followed 
by a 5-minute incubation at room temperature and 
centrifugation. The supernatant was discarded and a series 
of three washes were performed. The washed glassmilk beads 
were air-dried, followed by the addition of TE buffer and 
incubation for 5 minutes at 55°C to elute the DNA. The 
glassmilk beads were pelleted by centrifugation, followed 
by recovery of the supernatant, which was stored at -20°C 
until further use.
LIGATION OF DNA INTO A PLASMID VECTOR
A commercial pGEM®-T vector ligation kit from Promega was 
used for this study with the following protocol using the 
manufacturer's instructions. Briefly, MBG water, 2X Rapid 
Ligation Buffer, pGEM®-T Vector, T4 DNA Ligase and PCR 
product DNA were combined and incubated for 1 hour at room 
temperature or overnight at 4°C. The ligated DNA was 
stored at -20°C until use.
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MEDIA PREPARATION
LB (Lennox) media was used throughout this study, both in 
broth and agar forms (preparation described in Chapter II, 
Solutions).
TRANSFORMATION OF LIGATED DNA
The procedure for transformation was as follows according 
to directions provided by Promega, with one exception noted 
below. LB/Amp/IPTG/X—Gal plates were prepared and brought 
to room temperature. The ligated PCR product DNA:pGEM®-T 
Vector was combined with High Efficiency JM109 Competent 
Cells followed by incubation on ice for 20 minutes. The 
cells were heat-shocked, followed by a 2-minute incubation 
on ice. LB broth was added to each tube, and the bacterial 
culture was incubated for 1 hour in a 37°C shaker. 0.5ml 
of the culture was spread onto a LB/Amp/IPTG/X-Gal plate 
(the amount of the culture that was spread onto the agar 
plate was changed from original protocol). The culture was 
incubated overnight in a 37°C incubator, and blue-white 
screening was performed to verify the presence of the 
inserted DNA within the bacterial vector.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
59
As an additional step to verify the presence of and the 
size of the inserted DNA, another round of PCR was 
performed using the bacterial DNA from one white colony as 
the template. PCR was performed using the protocol 
outlined in Chapter II, Polymerase Chain Reaction.
PLASMID DNA PURIFICATION
The OIAprep Spin Miniprep Kit from Qiagen was used to 
purify the plasmid DNA. The protocol was as per the 
manufacturer, and is outlined in brief. LB broth and 
Ampicillin (Sigma) were placed into a centrifuge tube, 
inoculated with one PCR-verified white bacterial colony, 
and incubated overnight in a 37°C shaker. The bacterial 
cells were pelleted, and lysed via alkaline lysis. The 
sample was centrifuged, and the supernatant was applied to 
a QIAprep spin column (a silica-based column included in 
the Qiagen kit). The column was centrifuged, followed by a 
series of washes to remove contaminants. Adding MBG water 
to the column and centrifuging eluted the DNA, which was 
stored at -20°C until use.
JM109 competent cells (Promega) were used in the 
transformation reaction. The JM109 cells have high levels 
of nuclease activity, which can interfere with subsequent
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sequencing reactions. However, one of the washing steps 
(above) removes excess nucleases, enabling the purified DNA 
to be used successfully in later sequencing- reactions.
RESTRICTION ENZYME VERIFICATION
Prior to sequencing, a final verification was performed 
to ensure the proper size fragment was being sequenced. A 
restriction enzyme digest of the purified plasmid DNA was 
accomplished using SacI (Promega) and SacII (Promega) 
enzymes, which excised the insert from the vector without 
cutting the insert itself. The protocol was as follows 
according to the package insert provided b y  Promega. MBG 
water, plasmid DNA, 10X Multi-Core Buffer OCPromega), 
Acetylated BSA (Promega), SacI and SacII were combined and 
the sample was incubated in a 37°C water bath for one hour. 
The restriction enzyme digest was viewed viLa 
electrophoresis on a 1% agarose gel in IX UBE stained with 
ethidium bromide.
SEQUENCING OF THE hBUBl GENE
Sequencing was accomplished using an ALF Automated DNA 
Sequencer (Amersham Pharmacia Biotech). Tluis sequencer
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reliably sequences 500 base pairs. Since the hBUBl RT-PCR 
product was 1.2kb, internal primers were incorporated to 
break the 1.2kb product into three 400 base pair products 
(Figure 7). These shorter products were easily sequenced 
by the ALF Automated DNA Sequencer. All primers were 
labeled with Cy-5 (sequencer requirement) and purified by 
the manufacturer (Integrated DNA Technologies, Inc.) using 
HPLC to remove unincorporated dideoxynucleotides. The 
primers used were as follows (Cahill, personal 
communication):
Primer 1 Forward 5' -AGGGTTTTCCCAGTCACGAC-3'
Primer 2 Forward 5' -CCTCTGTACATTGCCTGGGC-3'
Primer 3 Reverse 5' -TATTTCTGGGCTCTCAATTCTTC-3'
Primer 4 Reverse 5' -CACACAGGAAACAGCTATGAC-3'
Primers 1 and 4 were located within the plasmid vector 
sequence, primer 2 was located at base pairs 347 through 
3 66 in the consensus hBUBl sequence and primer 3 was 
located at base pairs 803 through 825 in the consensus 
hBUBl sequence. Additionally, polyacrylamide gels designed 
for longer base pair sequencing were used (Repro-Gel Long 
Read by Amersham Pharmacia-Biotech) . The Epicentre 
SequiTherm Excel II Long Read DNA Sequencing Kit for ALF 
DNA Sequencers was used for the sequencing reaction 
according to the manufacturer's directions with exceptions




P C R  Forward Primer 
base pairs 49-70
CD1 NLS CD2






















Figure 7. hBUBl PCR and Sequencing Primer Locations
(A) The PCR primers spanned the CD1 and NLS regions of the 
hBUBl gene. A total of 1214 base pairs were amplified by 
PCR.
(B) Sequencing was accomplished using a set of four 
primers.
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noted below. In brief, a stock DNA template solution of 
100fmol/p.l was prepared using the following two step 
formula: 1) the number of picomoles per microliter was 
calculated, using the following formula, where N = the 
number of base pairs in the insert:
[DNA] y.g/y.1 x 106 x 1/660 x 1/N = pmol/pl 
2) one picomole of DNA was aliquoted into a microcentrifuge 
tube and MBG water was added to a final volume of lOy.1, 
resulting in a stock solution of 100fmol/y.l (the creation 
of a stock DNA template was not required in the original 
protocol). Then, MBG water, stock DNA template, sequencing 
buffer and labeled primer were combined to form a premix 
solution. For each reaction, four microcentrifuge tubes 
were labeled A,C,G or T. Termination Mixes were added to 
each of the four tubes, followed by the addition of the 
premix solution. Mineral oil was added to each tube, and 
the reactions were heated for 5 minutes at 95°C, followed 
by 30 PCR cycles according to the program provided my 
Epicentre. Stop/Loading Buffer was added to each reaction, 
and the reactions were incubated for 5 minutes at 95°C. 
Seven microliters of each reaction was loaded onto the 
sequencing gel (the amount loaded onto the sequencing gel 
was changed from the original protocol. The sequencer was 
run using the following parameters at constant power:
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The PCGene computer program was used to analyze all 
sequencing results. Alignment and translation of 
nucleotide sequences into corresponding amino acid 
sequences was also performed.
STATISTICAL ANALYSES
Statistical analyses were performed using the SPSS 
statistical analysis program. Two-sample t-tests and 
mulitivariate analysis of variances (ANOVA) were performed. 
Chi-squared analyses were computed using Microsoft Excel.





Series A  Patient: Data
Series A consisted of patients with AA and controls. AA 
was chosen because of the controversy of whether or not AA 
is a pre-leukemic disorder. All bone marrow samples in 
series A underwent both FISH analysis for chromosomes 7 and 
8 and sequencing of the hBUBl RT-PCR product. Bone marrow 
from 4 6 patients and six controls were analyzed in series 
A. Twenty-two out of 46 (47.8%) patients were male and the 
remainder (24; 52.2%) were female. The ethnic distribution 
of patients in series A was as follows: 4 patients (8.7%) 
were of Asian descent, 5 (10.9%) were African-American, 9 
(19.6%) were Hispanic and 24 (52.2%) were Caucasian. In 
four AA patients, ethnicity was not reported (Figure 8).
All patients had a complete karyotype performed by the 
National Institutes of Health in Bethesda, Maryland (Table 
1). All controls had a normal karyotype and no current or 
previous history of hematological disorders.
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Figure 8. Ethnic Distribution of Patients in Series A
Series A consisted of patients with AA. Series A samples 
underwent both FISH for chromosomes 7 and 8 and sequencing 
of the hBUBl RT-PCR product.
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Table 1. Karyotype Analysis of Patient Samples in Series A




37 46, xy [29]
39 4 6, xy
40 46,x x [31]
41 4 6, xx
42 46,x y [30]





64 4 6,x x [30]
77 4 6,x x [30]
81 46, xy
82 46,y,t(x;8) (p22.1; q24 .1)
85 4 6, xx
86 46, xy
87 4 6, xx
88 46,x y [30]
90 4 6, xx
95 4 6, xx
98 4 6,x x [30]
99 47.xy,+8[14]/4 6,xy[7]
101 4 6,x,-y [14]/4 6, xy[6]
111 46, xy [30]
113 46, xx
115 4 6, xx
116 4 6,x x [30]
117 4 6,x x [30]
121 46, xy
128 4 6,x x [30]
129 4 6,x x [30]
130 4 6, xx
137 46, xx [30]
139 4 6, xx
142 4 6,x x [30]
146 4 6,x y [21]
147 46,x y [30]
153 46, xx
157 4 6,x y [30]
166 46,x y [30]
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Table 1 Continued.
Patient # Karyotype Result
167 48,xxxc,+8[5]/47,xxxc[15]
168 Trisomy 8
169 4 6, xy
The patient number is listed with the corresponding 
karyotype analysis information. Seven patient samples 
(15.2%) showed an abnormal karyotype. The numbers in 
brackets [] indicate the number of cells counted.
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FISH Analysis for Chromosomes 7 and 8 on Series A  Patient 
Samples and Control Samples
Nick translation was used to incorporate labeled 
nucleotides into DNA to be used as probes FISH. 
Fluorescently labeled alpha-satellite DNA probes were used 
to detect the centromeric region of chromosomes 7 and 8 in 
a two-probe, two-color FISH analysis. FISH was performed 
on all patient samples in series A; 300 nuclei were 
analyzed for each sample.
The nuclei were scored as "normal" if two signals for 
each chromosome were present. Occasionally, nuclei 
contained multiple small signals joined by a thin 
filamentous line (Figure 9). These occurrences were scored 
as one signal. In cells undergoing DNA replication (S 
phase), the centromeric region is elongated. Alpha- 
satellite DNA FISH probes bind to the centromeric region of 
the chromosomes, and therefore may exhibit the appearance 
of a thin filamentous line in cells currently undergoing S 
phase (Litmanovitch, et al., 1998; Mukherjee et al., 1992). 
Any signals less than 1 diameter apart from each other were 
scored as one signal; however, this was a rare occurrence. 
To allow unbiased scoring, an independent person coded all 
samples. The code was broken only after the entire set of 
samples was scored. Each set included at least one control
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Figure 9. FISH Analysis for Chromosome 7
Example of a normal cell containing two copies of 
chromosome 7, with one copy presented as multiple small 
signals joined by a thin line (arrow). In this example, 
both cells were scored as normal, with each cell containing 
two copies of chromosome 7.
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and one patient sample.
Two out of 46 (4.3%) patient samples showed statistically 
significantly elevated levels of monosomy 7 (Figure 10,
Table 2) when compared to the control sample value of 1.55% 
monosomy 7. Bone marrow from patient 111 showed 4.0% 
monosomy 7, and bone marrow from patient 128 showed 5.17% 
monosomy 7. There were no patient samples exhibiting 
statistically significant levels of trisomy 7, where the 
control sample value was 0.4 6% trisomy 7. Two out of 46( 
4.3%) patient samples showed statistically significantly 
elevated levels of monosomy 8 (Table 2) when compared to 
the control sample value of 2.13% monosomy 8. Bone marrow 
cells from patient 58 had 5.3% monosomy 8, while bone 
marrow cells from patient 128 had 12.1% monosomy 8. Four 
out of 46 (8.7%) patient samples showed statistically 
significantly elevated levels of trisomy 8 (Table 2) when 
compared to the control sample value of 0.98% trisomy 8.
Bone marrow samples from patient 52 had 20.3% trisomy 8, 
patient 99 had 29.3% trisomy 8, patient 116 had 3.3% 
trisomy 8 and patient 168 had 10.3% trisomy 8. Bone marrow 
cells from patient 128 showed a high level of abnormality 
in both chromosomes 7 and 8 (monosomy 7 and monosomy 8) .
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Figure 10. FISH Analysis Showing Apparent Monosomy 7
This photograph shows the detection of monosomy 7 using 
FISH in a metaphase cell. Only one signal is shown for 
chromosome 7 (arrow), indicating apparent monosomy for that 
chromosome.




Patient Samples in Se=ries 
Cytogenetic Abnormali-ties
;A Showing Elevated 
with Control Data
Patient # % Monosomy 7 % Trisomy 7 % Monosomy 8 % Trisomy 8
52 2.67 0.67 0.33 20.33*
58 2.00 0. 00 5.33* 0.00
99 0.67 0.00 2.67 29.33*
111 4.00* 0.67 4.33 2.67
116 2.67 1. 00 1.00 3.33*
128 5.17* 0. 00 12.07* 1.72
168 1.67 0.00 4.00 10.33*
♦Statistically Significant
Control ¥ % Monosomy 7 % Trisomy 7 % Monosomy 8 % Trisomy 8
Con 1 0.66 1.33 1. 66 0. 66
Con 2 2.29 0.76 6.10 1.52
Con 5 2.00 0. 66 1.33 0. 66
Ded 4 1.66 0. 00 1.00 1.33
Ded 5 1.00 0.00 0.33 1.00
Ded 6 1.66 0.00 2.33 0 . 66
Percent aneuploidy £or chromosomes 7 and 8 for patient
samples in series A, versus con.trol sample data, for
patient samples that showed a s tatistically significant
level of aneuploidy.
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In comparison with data obtained by karyotype analysis, 
FISH detected abnormalities not detected by karyotype in 4 
of 7 patient samples (Table 3) . This lead to the 
conclusion that FISH is approximately twice as sensitive in 
detecting cytogenetic abnormalities than karyotype analysis 
in this study.
Analysis of the Mitotic Index (MI) in Patient Samples from 
Series A  and Control Samples
The MI is an indication of the cell cycle frequency. For 
this study, the MI was determined by counting the number of 
cells in metaphase and dividing by the total number of 
cells scored. Cells were determined to be in metaphase if 
individual chromosomes were visible (such as Figure 10).
The MI was examined since, hypothetically, hBUBl would have 
a higher level of expression in a population of cells 
undergoing rapid division. For this study, the MI was 
calculated (Chapter II) simultaneously while performing 
FISH analysis on unstimulated bone marrow cells. The 
average MI for control samples was 0.33%, while the average 
MI for patient samples in series A was 0.44%. There was no 
statistically significant difference between the patient 
and control samples (p=0.571). A rapidly dividing cell 
line, HL60, assayed by Dr. Michael Stacey, was found to
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Table 3. Karyotype versus FISH Results in Series A 
Patients Showing Elevated Levels of Aneuploidy 
Patient # FISH Result Karyotype Result
52 + 8 (20.33%) 47,xy,+8[13]/46, xy[7]
58 -8 (5.33%) 46, xy
99 +8 (29.33%) 47.xy,+8[14]/46,xy[7]
111 -7 (4.00%) 46, xy [30 ]
116 + 8 (3.33%) 4 6,xx[30]
128 -7 (5.17%) 46,xx[30]
-8 (12.07%)
168 + 8 (10.33%) trisomy 8 (exact number
not available)
Samples from patients 58, 111, 116 and 128 showed elevated
levels of chromosome abnormalities for chromosomes 7 and/or 
8. In these patients, the abnormalities were not detected 
by karyotype analysis. Numbers in brackets [] indicate the 
number of cells.
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have a MI of 2.2% in exponentially growing cells, six times 
higher than the control sample MI rate in this study 
(Stacey, personal communication). For this reason, HL60 
cDNA was used as the positive control for the hBUBl- 
specific RT-PCR. It is known that hBUBl is more abundant 
during active cell division, therefore, a cell line (such 
as HL60) with an increased number of cell divisions would 
have elevated expression of hBUBl, allowing for easy 
amplification in a RT-PCR reaction.
hBCZBl-Specific RT-PCR on RNA from Patient and Control 
Samples in Series A
PCR was performed on cDNA, constructed from total RNA, 
for all patients in series A. Ten out of 46 (21.7%) series 
A  patient cDNA samples amplified the expected 1.2kb hBUBl 
RT-PCR product (Figure 11). cDNA from each patient sample 
underwent two separate, but identical rounds of hBUBl- 
specific PCR for verification. All 3 6 patient cDNA samples 
showing no hBUBl RT-PCR product were re-analyzed by an 
additional round of PCR using primers for the ubiquitously 
expressed gene actin. All 36 patient cDNA samples (100%) 
amplified the expected ~550 base pair actin PCR product, 
verifying that each RNA sample was intact and not degraded 
(Figure 12).
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1 2  3 4  5 6  7 8
1.6 kb Expected






9 10 11 12 13 14 15 16
Figure 11. Gel Electrophoresis of hBUBl-specific RT-PCR.
Lanes 1 and 9 contain a 1 kb DNA ladder. Lanes 2-5 contain 
patient cDNA samples showing the expected ixBDBl-specific 
RT-PCR product of 1.2kb. Lanes 10-14 contain patient cDNA 
samples showing no amplification of the hBUBl-specific RT- 
PCR product. Lane 15 contains the hBUBl-specific RT-PCR 
reaction completed on cDNA from HL60, which was used as the 
positive control. Lane 16 contains the negative control, 
and lanes 6-8 are empty.
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1.0 kb 
0.5 kb .Expected -550 bp 
Actin PCR 
product
Figure 12. Gel Electrophoresis of Actin PCR.
Lane 1 contains a 1 kb DNA ladder. Lanes 2-7 contain 
patient cDNA samples showing the expected Actin PCR product 
of -550 base pairs.
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All 36 patient RNA samples that showed no hBUBl RT-PCR 
product underwent a second round of cDNA synthesis. In the 
second cDNA synthesis, an hBUBl oligonucleotide reverse PCR 
primer (spanning base pairs 1195-1215 in the normal 
consensus sequence) was used in place of the Oligo(dT)is 
primer. This was performed to ensure that the cDNA 
synthesis began at the 3' end of the NLS region within the 
hBUBl RNA, thereby increasing the likelihood of successful 
cDNA synthesis provided that hBUBl was being expressed.
This ensured that cDNA synthesis could occur even if the 
hBUBl RNA past the 3' end of the NLS region was degraded. 
The cDNA synthesized using the hBUBl oligonucleotide 
reverse PCR primer was subjected to a new round of hBUBl- 
specific PCR. Once again, all 3 6 patient cDNA samples 
showed no amplification of the hBUBl RT-PCR product (Figure 
13). HL60, the rapidly dividing cell line, chosen as the
PCR positive control, consistently amplified the correct 
1.2kb hBUBl RT-PCR product (Figure 11).
cDNA was synthesized from total RNA isolated from five 
control bone marrow samples using the 01igo(dT)i5 primer. 
hBUB 1-specific PCR was performed on the cDNA, and three out 
of 5 samples (60%) amplified the correct 1.2kb hBUBl RT-PCR 
product. The remaining two showed no hBUBl RT-PCR product. 
Due to lack of material, the control samples did
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36 samples undergo a 
round of actin-specific PCR
36 samples do not amplify the 
expected 1.2 kb hBUBl 
RT-PCR product (100%)
All 36 new cDNA samples undergo 
another round of hBUBl-specie  
PCR in duplicate
36 samples do not amplify 
the expected 1.2 kb hBUB 1 
RT-PCR product (78.3%)
All 36 samples amplify the expected 
actin PCR product (100%) 
(RNA is intact and not degraded)
10 samples amplify the 
expected 1.2 kb hBUBl 
RT-PCR product (21.7%)
All 36 patient samples undergo 
cDNA synthesis again using 
the hBUBl oligonucleotide 
reverse PCR primer
46 RNA samples from patients 
in series A undergo cDNA 
synthesis using the 
Oligo(dT)15 primer
46 cDNA samples from 
patients in series A 
All undergo hBUBl-specific 
PCR in duplicate
Figure 13. Flow Chart for cDNA Synthesis and hBUBl- 
specific RT-PCR in Patient Samples from Series A
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not undergo PCR for actin or additional cDNA synthesis 
using the hBUBl oligonucleotide reverse PCR primer. To 
provide more accurate results, the number of control 
samples should be increased, however only five control 
samples were available at the time of this study.
Sequencing of the hBUBl RT-PCR Product in Patient Samples 
from Series A  and Sequencing of the HL60 RT-PCR Positive 
Control
The cDNA from the ten patient samples in series A that 
exhibited the correct 1.2kb hBUBl RT-PCR product were 
sequenced to look for base pair changes within the hBUBl 
CD1 and NLS regions. In addition, cDNA from the PCR 
positive control HL60 was also sequenced. Sequencing was 
performed first 1214 base pairs, which spanned the first 
conserved domain and the nuclear localization sequence in 
the hBUBl gene (Figure 14). hBUBl is comprised of 3446 
base pairs, and consists of 25 exons. All base pair 
changes are referenced according to their base pair 
location within the entire hBUBl consensus sequence, as 
reported by Cahill et al. (1998).
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CATGGACACCCCGGAAAATGTCCTTCAGATGCTGGTGAATGGGAAAGATACATACAGTG 
G GTAGAAGAGAAT T T T C C T GAGAATAAAGAATAC T T GATAAC T T TAC TAGAACAT T TAA 










TCCT T TGAAGAAT TGAGAGCCCAGAAATACAAT CAACGGAGAAAGCAT GAGCAAT GGGT 






T T T GAAAGCCCAGACAGTAACAGACTCCATGT T TGCAGTGGCCAGCAAAGATGC
Figure 14. Consensus Sequence of the hBUBl RT-PCR Product
Underline indicates a PCR primer location. Bold indicates 
an internal sequencing primer location.
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Initially, direct-from-PCR sequencing was attempted to 
reduce artifacts and preparation time. However, results 
from direct-from-PCR sequencing reactions were of poor 
quality when compared to results obtained by cloning first. 
For that reason, cloning prior to sequencing was used for 
this study. Sequencing was accomplished by cloning the PCR 
product into a plasmid vector, transformation of the 
ligated PCR product and purification of the plasmid DNA. 
However, a disadvantage encountered when cloning each 
colony contains only one of the two alleles. Therefore, 
each sequence obtained represents only one of the two hBUBl 
alleles present. This issue can be resolved by sequencing 
multiple colonies from the same reaction to ensure that 
both alleles are sequenced.
Due to variations in the amount of extracted nucleic 
acids, each sample underwent a different number of reverse 
transcription reactions, PCR reactions and/or sequences. 
Ideally, each individual patient RNA sample would have 
undergone five separate reverse transcription reactions. 
Each of the five resulting cDNAs (per patient) would have 
undergone separate rounds of hBUBl-specific PCR. Finally, 
each PCR reaction would have been separately cloned and 
sequenced. The end result would have been five separate 
sequences for each patient sample, and a confidence
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interval of 80%. Statistically, 20 separate cDNA 
syntheses, PCR reactions and sequences should be performed 
on each patient sample to establish a confidence interval 
of 95% (Cahill, personal communication). Artifacts can be 
introduced at the reverse transcription stage, the PCR 
stage, or during sequencing. However, by increasing the 
number of RT-PCR and sequence analyses, the likelihood of 
error is reduced. The maximum possible number of RT-PCR 
and sequencing replications were performed on each patient 
sample in an effort to rule out potential artifacts. Each 
patient sample underwent between one and seven RT-PCR and 
sequencing reactions, depending on the sample availability. 
In addition, since each bacterial colony contains just one 
of the two hBUBl alleles, every time a colony was 
sequenced, there was a 50/50 possibility of sequencing 
either allele. In the instances where only one sequence 
determination was performed and shown to be normal, it is 
possible that the other allele could have been mutant, and 
vice versa. In these cases, the results obtained were 
inconclusive.
RNA from patient 42 underwent one round of RT-PCR and 
sequencing. Since only one RT-PCR and sequencing reaction 
was performed, the power of the results was reduced, and 
therefore the results should be evaluated cautiously.
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Sequencing of hBUBl in the RT-PCR product sample from 
patient 42 indicated two base pair changes located at base 
pairs 824, 924 and an insertion. The insertion consisted 
of 11 extra base pairs inserted within the oligonucleotide 
forward PCR primer sequence. The significance of this 
insertion, if any, is unknown. Due to the lack of 
additional sequence information, the preliminary results 
for patient 42's sample are inconclusive (Figure 15, Table 
4) .
RNA from patient 43 underwent one round of RT-PCR and 
sequencing. Sequencing of the hBUBl RT- product indicated 
two base pair changes at base pairs 845 and 117 0. Again, 
due to the lack of additional sequence data, concrete 
conclusions cannot be drawn (Figure 16, Table 4).
RNA from patient 52 underwent two separate rounds of RT- 
PCR (PCR #1 and #2). When sequenced, the DNA recovered 
from PCR #1 showed no base pair changes, while the DNA 
recovered from PCR #2 showed a base pair change at base 
pair 472 and an insertion/deletion. The insertion was very 
similar to the insertion found in patient sample 42, and 
consisted of 12 extra base pairs inserted within the 
oligonucleotide forward PCR primer sequence, followed by a 
five base pair deletion. The significance of this 
insertion/deletion, if any, is unknown. A  preliminary










RT #1 -5 /5 /9 9
PCR #1 -8 /10 /00
Ligate 9/18/00
Patient 42  
RNA Sample
Result 
2 base pair changes 
(bp 824 & 927) and an insertion
Sequencing Flow Chart for Patiemt 42
results indicate two base pair changes and an 
However, these sequencing results were not
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R T  **1 - S / 5 / 9 9
P C R  **1 - 8/1 0 / 0 0
G e n e c l e a n  8 / 2 4 / 0  O
T r a n s f o r m  9 / 7 / 0 0
Ligate 8 / 2 8 / 0 0
Purify 9/1 5 / 0 0
S e q u e n c e  9 / 2 2 / 0 0
Patient 4 3  R N A .  S a m p l e
R e s u l t  2  b a s e  pair c h a n g e s  ( b p  8 4 5  &  11 T O )
Figure 16. Sequencing Flow Chart for Patient 43
Preliminary results indicate two base pair changes. 
However, these sequencing results were not duplicated.
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observation is that the base pairs inserted within the 
forward primer area in both patient samples are very- 
similar to the base pairs from the plasmid vector, which 
can be found immediately prior to the forward primer 
starting point in the normal consensus sequence. Perhaps 
there was an error during ligation in which the ligation 
area on the 5' end of the RT-PCR product was disturbed, or 
the insertion(s)/deletion may be due to a polymerase error. 
Due to the lack of additional sequence information, the 
preliminary results for patient 52's sample are 
inconclusive (Figure 17, Table 4).
The RNA from patient 82 underwent two rounds of reverse 
transcription. The product from the first reverse 
transcription reaction underwent one round of PCR (PCR #1) , 
followed by cloning and sequencing. The product from the 
second reverse transcription reaction underwent six 
separate PCR reactions (PCR #2-#7), followed by cloning and 
sequencing. The DNA recovered from PCR #1 was sequenced 
five times, which ruled out the possibility of a sequencing 
artifact, however, the DNA from PCR #2-#7 was only 
sequenced once. The sequencing results from PCR #1 showed 
four base pair changes located at base pairs 418, 532, 632
and 908. The sequencing results from PCR #3 showed two 
base pair changes located at base pair 711 and 1107. The
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Genedean 1/29/99 Genedean 8/24/00
PCR #1 - 1/22/99
RT #1 -1/18/99
Ligate 8/28/00
PCR #2 - 8/10/00











1 base pair change 
(bp 472) and an insertion/deletion
Result 
No base pair changes
Figure 17. Sequencing Flow Chart for Patient 52
Preliminary results indicate one base pair change and an 
insertion/deletion in the sequencing of DNA from PCR #2, 
while the other sequence was normal, making the results 
inconclus ive.
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sequencing results from PCR #4 showed one base pair change 
at base pair 1177. The remaining four PCR reactions showed 
no base pair changes within their sequences. None of the 
base pair changes were seen in duplicate, and were most 
likely artifacts. The RNA from patient 82 underwent the 
most sequencing reactions (seven in total) out of the ten 
patient samples analyzed from series A. The high level of 
sequence variation in this patient sample showed that the 
potential for artifacts was high among these experiments. 
The overall sequencing data from patient 82's sample 
indicated that the majority of sequences performed had no 
base pair changes detected. Therefore, it is reasonable to 
conclude that the remaining sequence variations were 
artifacts (Figure 18, Table 4) .
RNA from patient 90 underwent two rounds of RT-PCR and 
sequencing. Sequencing of both RT-PCR products showed no 
base pair changes within the hBUBl sequence. Therefore, it 
is reasonable to conclude, preliminarily, that the sequence 
data obtained from patient 90 is identical to the normal 
consensus sequence data reported by Cahill et al (1998) 
(Figure 19, Table 4).
RNA from patient 117 underwent one round of reverse 
transcription followed by two separate PCR analyses. Both 
PCR products were cloned and sequenced. The product from
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PCR H  - 1/2/99
CeaedcM 6/21/00 G a te d ca i 6/21/00 Gcaedeia t/4/99 G otedeto S/4/99
T tu u fo m  t/9 /99
Result 
No btse p u r  changes
Result 
No base p u r  changes
Remit 
2 base p u r  disages 
(bp 711 &  1107)
Resdt 
4 base p a r  diaages 
(b p 4 H .5 3 2 .6 3 2  A  90S)
Resvlt 
No base p u r  dtasges
Resalt 
No base p u r  diaages
Seqoeace t/20/99
Figure 18. Sequencing Flow Chart for Patient 82
Preliminary results indicate four base pair changes in the 
sequence from PCR #1, 2 base pair changes in the sequence 
from PCR #3, and 1 base pair change in the sequence from 
PCR #4, all of which are different. The remaining 
sequencing reactions showed no base pair changes. These 
results are contradictory.
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# 1  - 2 / 2 2 / 9 9
**1 - 4 / 1  2 / 9 9 # 2  - S/1 0 / 0 0
4 / 2 7 " / 9 9
L i g a t e  4 / 2 8 / 9 9 L i g a t e  8 / 2 8 / 0 0
T r a  n  s f o T r a n s f o r m  9 / 1 3 / 0 0■4-/28/99
P u  rity S / 1  3 / 9 9 F»urrfy 9 / 1  S / O O
P a t i e n t  9 0  R N A  S a m p  I
R e s u i  It ISIo b a s e  p a i r  c h a n g e s
R e s u  It 
INIo b a s e  pai r  c h a n g e s
1 1 / 1  / O OS e q u e n c e  S / 3 1 / 9 9 ,  S / 8 / 9 9
Figure 19. Sequencing Flow Chart for Patient 90
Preliminary results showed both sequences with no base pair 
changes, indicating that the sequence was the same as the 
normal consensus sequence reported by Cahill et al., 1998.
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PCR #1 was sequenced six times and preliminary results 
indicated that there were no base pair changes present in 
any of the six sequencing reactions. All six sequencing 
reactions were performed on DNA from a single colony. The 
second PCR product was sequenced once, and one base pair 
change was observed at base pair number 1055 in the hBUBl 
normal consensus sequence. The sequencing results were 
conflicting, showing a 50% probability that the sequence 
obtained was normal and a 50% probability that the sequence 
obtained contained a base pair change. Considering the 
high risk of artifacts in this study, it is possible that 
the base pair change seen is in fact an error. However, at 
this point, the data is inconclusive (Figure 20, Table 4).
RNA from patient 121 underwent three separate rounds of 
RT-PCR (PCR #l-#3). The DNA recovered from PCR #1 and #3 
showed no base pair changes upon sequencing; however, the 
DNA recovered from PCR #2 showed two base pair changes at 
base pairs 615 and 1151. The majority of the sequencing 
data indicated that no base pair changes were present, 
therefore there is a high probability that the two base 
pair changes observed are artifacts. It is reasonable to 
conclude that patient 121's sample is most likely normal, 
with no base pair changes present (Figure 21, Table 4).








Rurify 5/1 3/9 9
Genedean 8/24/00
Transform 8/30/00





No base pair changes
Result 







Figure 20. Sequencing Flow Chart for Patient 117
Preliminary results indicate one base pair change in the 
sequence from PCR #2, with the other sequence as normal, 
making the results inconclusive.
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Ligate 8/28/00 Ligate 8/28/00
Purify 9/1 5/00 Purify 9/1 5/00Purify 5/1 3/99
Genedean 8/24/00
Transform 9/7/00




RT #2 -  3/1 8/00
Genedean 5/6/99
PCR #2  -  8/1 0/00 PCR #3 - 8/1 0/00
RT #1 -2 /2 2 /9 9








2 base pair changes 
(bp 615 & 1 151)
Result 
No base pair changes
Result 
No base pair changes
Figure 21. Sequencing Flow Chart for Patient 121
Preliminary results indicate two base pair changes in the 
sequence from PCR #2, and no base pair changes in the other 
two sequences, leading to the conclusion that the sequence 
is most likely normal.
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The RNA from patient 129 underwent one round of RT-PCR 
and sequencing. Sequencing results showed no base pair 
changes were present. As with all patient samples that 
were sequenced only once, the results are inconclusive 
(Figure 22, Table 4).
RNA from patient 137 underwent two rounds of reverse 
transcription. The product from the first reverse 
transcription reaction subsequently underwent two separate 
rounds of PCR (PCR #1 and #2) , while the product from the 
second reverse transcription reaction underwent only one 
round of PCR (PCR #3). When sequenced, the DNA recovered 
from PCR #1 showed no base pair changes present. DNA from 
PCR #2 showed five base pair changes located at base pairs 
327, 844, 8 68, 975 and 1227. The sequencing results from 
the DNA recovered from PCR #3 showed one base pair change 
at base pair 470. As with patient 82, none of the base 
pair changes were present in duplicate. In addition, the 
probability of six base pair changes occurring within 1214 
base pairs is rare, and would indicate an extremely high 
mutation rate. If that were the case, the base pair 
changes would have been detected in other samples and found 
in duplicate. The actual probability of this many 
different base pair changes occurring is very low; 
therefore, the base pair changes seen are most likely
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Patient 1 29 
RNA Sample
RT **-1 - 9/1 S/99
PCR #1 - 9/21/99
Genedean "I "I / I  8/99
Ligate 1 1 /3/0 O
ransform "I "I /3 /0 O
Purify "I -i /~r/oo
Sequence "1 1/"I 5/0O
No bas
R e s u  It e  pair- c h a n g e ;
Figure 22. Sequencing Flow Chart for Patient 129
Preliminary results indicate no base pair changes; however, 
the lack of additional sequence information makes the 
results inconclusive.
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artifacts. Nevertheless, the sequencing data for patient 
137 is conflicting, and a concrete conclusion cannot be 
MADe (Figure 23, Table 4) .
The RNA from patient 153 underwent one round of RT-PCR 
and sequencing. The sequence data for patient 153 showed 
five base pair changes located at base pairs 645, 930, 931, 
932 and 933. The sequential base pair changes were unique 
to patient 153, and were not seen elsewhere. Due to the 
lack of additional sequencing data, these results are 
inconclusive (Figure 24, Table 4).
Sequencing of the HL60 hBUBl-specific RT-PCR product 
revealed no base pair changes, and was consistent with the 
normal consensus sequence reported by Cahill et al. (1998). 
Any potential polymorphism or mutation that does not result 
in a change in the amino acid sequence, does not affect the 
protein sequence. Therefore, any base pair change that does 
not have a corresponding amino acid change would most 
likely be inconsequential.























No base pair changes
Result 
1 base pair change 
(bp 470)
Re-suft 
5 base patir changes 
(bp 327. 844. 8*68, 975 & 1227)
Figure 23. Sequencing Flow Chart for Patient 137
Preliminary results indicate fi_ve base pair changes in the 
sequence from PCR #2, 1 base pair change in the sequence 
from PCR #3 (all different) , and no base pair changes in 
the sequence from PCR #1, making the results conflicting 
and inconclusive.







P C R  9/21/99




5 base pair changes 
(bp 645 , 930 , 931, 932 & 933)
Figure 24. Sequencing Flow Chart for Patient 153
Preliminary results indicate five base pair changes; 
however, the lack of additional sequence information makes 
the results inconclusive.
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Table 4. Summary of Base Pair Changes/Amino Acid Changes 
in Patient Samples Sequenced from Series A with 
Corresponding FISH Analysis
Patient # FISH Result PCR# BP# BP Change Amino Acid Change
42 Normal #1 ins 11 bp ins Protein unable
824 T->C to be
937 T-»C translated
43 Normal #1 845 G-^A Glu-^Lys
1170 T-»C No change
52 +8 (20.33%) #2 ins/ 12 bp Protein unable
del ins/5 to be
472 bp del translated
G-»A
82 Normal #1 418 G-»A No change
532 T-»C No change
632 G->A Gly-^Arg
908 C-»T Gln->stop
#3 711 T-»A Val-»Glu1107 A->G No change#4 1177 A->C No change
117 Normal #2 1055 A->T Arg->stop
121 Normal #2 615 A~>G Gln-^Arg
1151 G-»A No change
139 Normal #2 327 G-»A Gly*^Glu
844 T*>C No change
868 A-^G No change
975 A-»G Glu->Gly1227 T->C Val~^Ala#3 470 A->G Arg->Gly
153 Normal #1 645 C-»T Ser^Leu
930 A-»G \
931 T“»C MetAspGluLeu~>
932 G->C MetGlyArgLeu933 A->G /
Comparison of FISH data and sequencing results for hBUBl.
Abbreviations: BP=base pair ; ins:=insertion ; del=deletion
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Statistical Analyses on Data from Patient Samples in Series 
A
Statistical analyses were performed using the SPSS 
computer software program. The data obtained from the FISH 
analyses for aneuploidy rates in chromosomes 7 and 8 were 
evaluated using a two-sample t-test. The results showed 
that there was no statistically significant difference 
between the average level of aneuploidy in the patient 
samples versus the control samples (p=0.453 for monosomy 7, 
p=0.194 for trisomy 7, p=0.840 for monosomy 8 and p=0.685 
for trisomy 8).
To allow comparison of individual patient data and 
control data, a chi-squared analysis was performed. The 
results from the chi-squared analysis show that two out of 
46 patients (4.3%) showed statistically significantly 
higher levels of monosomy 7, two out of 4 6 patients (4.3%) 
showed statistically significantly higher levels of 
monosomy 8 and four out of 4 6 patients (8.7%) showed 
statistically significantly higher levels of trisomy 8.
One patient sample showed elevated levels of both monosomy 
7 and monosomy 8 (2.2%) (outlined previously in Table 2).
A statistical comparison was performed to check the 
effect of age, race, and responsiveness to treatment with 
respect to aneuploidy. An analysis of variance was
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performed using the SPSS computer program, and the only 
statistically significant result showed that African- 
American males were more likely to exhibit monosomy for 
chromosome 8 (p=0.016), however the sample size was low.
Responsiveness to treatment and age of the patient did not 
correlate with the level of aneuploidy for either 
chromosome 7 or 8.
SERIES B
Series B Patient Data
One hundred and forty-three additional patient samples 
underwent RT-PCR and sequencing analysis for hBUBl without 
FISH analysis. The patient samples in series B consisted 
of 49 patients with AA, 63 patients with MDS, 8 patients 
with pancytopenia, 6 patients with PNH, 3 patients with 
anemia, 3 patients with PRCA, 3 patients with 
thrombocytopenia, 2 patients with myeloproliferative 
disease, 2 patients with neutropenia, 1 patient with 
porvovirus, 1 patient with LGL, 1 patient in transformation 
to leukemia and 1 patient with "liver transplant" as the 
diagnosis (Figure 25). The sex of the patient was known 
for 136 out of 143 patients; 52 out of 143 (36.4%) were 
female and 85 out of 143 (59.4%) were male. The ethnic
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Figure 25. Distribution of Bone Marrow Disorders in Series 
B Patients
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distribution of patients in series B showed that eight out 
of 143 (5.6%) were Asian, ten out of 3_43 (7.0%) were 
African-American, 13 out of 189 (9.1%) were Hispanic and 82 
out of 143 (57.3%) were Caucasian. In 30 patients (21.0%), 
ethnicity was not reported (Figure 26) . Sixty-eight 
patients out of 143 (47.6%) had a complete karyotype 
performed by the National Institutes o f  Health in Bethesda, 
Maryland (Appendix A) . The remaining 75 patients did not 
undergo karyotypic analysis.
hBDBl-Specific PCR on cDNA from Patients in Series B
PCR was performed on cDNA constructs from all 143 patient 
samples. Twenty-one out of 143 (14.7g) patient samples 
amplified the expected 1.2kb hBUBl RT— PCR product. One 
hundred and twenty-two out of 143 (85 — 3%) patient samples 
did not amplify a 1.2kb hBUBl RT-PCR product during the 
first round of hBUBl-specific RT-PCR. The cDNA used in the 
first round of hBUBl-specific PCR was synthesized using the 
0ligo(dT)i5 primer. Each PCR reaction was performed in 
duplicate for verification of results- All 122 patient 
samples with no hBUBl RT-PCR product were re-analyzed by 
another round of PCR for the ubiquitoosly expressed gene 
actin. One hundred and sixteen out ofr 122 (95.1%) patient 
samples amplified the expected ~500 base pair actin PCR















Figure 26. Ethnic Distribution of Patients in Series B
Series B consisted of patients with, a variety of bone 
marrow disorders (Figure 25) . Series B samples underwent 
sequencing of the hBUBl RT-PCR product without FISH 
analysis.
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product. Six patient samples did not amplify any actin PCR 
product. Therefore, it was assumed that the six patient 
samples that did not amplify the actin PCR product had 
degraded RNA. For the other 116 patient samples, the 
correct amplification of the actin product verified that 
the RNA was intact and not degraded. All patient samples 
that showed no hBUBl RT-PCR product, but did amplify the 
expected actin PCR product underwent a second round of cDNA 
synthesis. In the second cDNA synthesis, the hBUBl reverse 
oligonucleotide PCR primer was used in place of the 
Oligo(dT)i5 primer (Figure 27). As stated in Chapter II, 
the synthesis of new cDNA using the hBUBl oligonucleotide 
reverse PCR primer was performed to increase the likelihood 
of successful cDNA synthesis of hBUBl, provided that the 
gene was being expressed. The cDNA synthesized using the 
hBUBl oligonucleotide reverse PCR primer was subjected to a 
new round of hBUBl-specific PCR. Twenty-two of the 122 
patient samples that underwent the second round of reverse 
transcription using the hBUBl oligonucleotide reverse PCR 
primer, followed by a second round of hBUBl specific PCR, 
amplified the correct 1.2kb expected hBUBl RT-PCR product. 
These samples were then combined with the patient samples 
that showed amplification of the expected hBUBl RT-PCR 
product during the first PCR reaction using the 01igo(dt)is
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hBUBl 
RT-PCR with 01igo(dT)l5 primer
CD1 NLS CD2 3446
01igo(dT)ls R T -P C R  primer 
cD N A  synthesis starting point
RT-PCR with hBUBl reverse PCR primer
CD1 NLS CD2 3446
hBUBl reverse PCR prim er 
cD N A  synthesis starting point
Figure 27. hBiTBl-Specific RT-PCR Primer Locations
Graphical representation of the location of the RT-PCR 
primers used in this study. The 01igo(dT)is primer begins 
cDNA synthesis at the poly A tail, whereas the hBUBl 
reverse PCR primer, when used in reverse transcription in 
place of the 01igo(dT)i5 primer, begins cDNA synthesis at 
the 3' end of the NLS region in hBUBl.
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primer. In total, 43 out of 143 samples (30.1%) amplified 
the hBUBl expected RT-PCR product in this additional 
patient set (Figure 28). The 30.1% of patient samples from 
series B that amplified the hBUBl RT-PCR product is 
slightly higher than the 21.7% of patient samples from 
series A that amplified the hBUBl RT-PCR product.
Potential reasons for the lack of hBUBl RT-PCR 
amplification are discussed further later in this Chapter.
Sequencing of the hBUBl RT-PCR Product in Patient Samples 
from Series B
Of the 43 patient samples that correctly amplified the 
1.2kb hBUBl expected RT-PCR product, 14 were subsequently 
sequenced. All 14 samples underwent one round of reverse 
transcription, PCR and sequencing. Therefore, these 
results must be viewed as preliminary. Further sequencing 
is necessary to increase the confidence interval, and 
reduce the error introduced by only one sequencing reaction 
performed for each patient.
Samples from patients 34, 80, 84, 96, 102, 108, 110, 133,
140, 144 and 179 showed no base pair changes present in the 
CD1 or NLS regions of the hBUBl RT-PCR product. Patient 
46's sample showed one base pair change at base pair 726; 
patient 132's sample showed one base pair change at base
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122 samples undergo a 
round of actin-specific PCR
122 samples do not amplify 
the expected 1.2 kb h B U B l 
RT-PCR product (85.3%)
All 116 new cDNA samples undergo 
another round of hBU81-specific 
PCR in duplicate
6 samples do not amplify the expected 
actin PCR product (4.9%)
(RNA is degraded)
116 samples amplify the expected 
actin PCR product (95.1%) 
(RNA is intact and not degraded)
21 samples amplify the 
expected 1.2 kb h B U B l  
RT-PCR product (14.7%)
22 samples amplify the expected 
1.2 kb h B U B l RT-PCR product (19.0%)
94 samples do not amplify the 
expected 1.2 kb h B U B l 
RT-PCR product (81.0%)
116 patient samples undergo 
cONA synthesis again using 
the h B U B l oligonucleotide 
reverse PCR primer
143 RNA samples from patients 
in series B undergo cDNA 
synthesis using the 
Oligo(dT)15 primer
143 cDNA samples from 
patients in series B 
All undergo hBUB  1-specific 
PCR in duplicate
Equals a combined total of 
43 patient samples that 
amplified the expected 
1.2 kb hB U B l RT-PCR product (30.1 %)
Figure 28. Flow Chart for cDNA Synthesis and hBUBl- 
specific RT-PCR in Patient Samples from Series B
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pair 566, and patient 136's sample showed two base pair 
changes at base pairs 358 and 731 (Table 5). Again, these 
base pair changes were not seen in duplicate, and may- 
likely be artifacts. Given the results from the previous 
extensive sequencing, there was a high frequency of 
potential artifacts (see end of next paragraph).
Assessment of PCR Conditions
In sequencing patient samples from both series A and 
series B, I was concerned by the high prevalence of base 
pair changes in some samples. The normal DNA mutation rate 
is about one in 108 (0.0000001%) base pairs per cell 
generation (Alberts et al., 1989). Single nucleotide 
polymorphisms occur in one out of every one to two thousand 
base pairs (Osgood, personal communication). Therefore, 
five or six base pair changes in a span of 1214 base pairs 
is unusually high. In a retrospective analysis, I noticed 
that PCR reactions performed after August 20, 1999 were 
completed using a different Taq DNA Polymerase. The 
protocol after August 20, 1999 utilized a lower grade of 
Taq Polymerase in the PCR reactions. A  low grade Taq 
Polymerase may have a higher frequency of error when 
compared to a high quality Taq Polymerase, which has an
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Table 5. Summary of Sequencing Results and Diagnoses for 
Patient Samples from Series B
Patient # Diagnosis BP# BP Change Amino Acid Change
34 AA/PRCA No base pair changes
46 MDS 726 C“»T Ala~>Val
80 LGL No base pair changes
84 MDS No base pair changes
96 Transformation 
to Leukemia
No base pair changes
102 MDS No base pair changes
108 MDS No base pair changes











140 MDS No base pair changes
144 AA/Hepatitis B No base pair changes
179 AA No base pair changes
Comparison of diagnosis for patients in series B to the 
sequencing results obtained.
Abbreviations: BP=base pair
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error rate of about 3.2 mutations induced per 100,000 base 
pairs (0,0032%) (Epicentre Technical Support, personal 
communication) . Due to the number of base pair changes in 
sequences from PCR reactions completed prior to August 20, 
1999 when compared to sequences from PCR reactions 
completed after August 20, 1999, a retrospective analysis 
was performed to compare these two subgroups.
In looking at the sequencing reactions performed, one can 
divide the group of sequences into those that showed base 
pair changes and those that did not show any base pair 
changes (Table 6). Ignoring patient identifier data, and 
only looking at the sequences as a whole, it is obvious 
that a large percentage of the sequences that exhibited one 
or more base pair changes were completed after August 20, 
1999. In addition, the majority of sequences that showed 
no base pair changes were completed prior to August 20,
1999 (Figure 29). As a final observation, there is an 
inverse correlation between the number of base pair changes 
detected and my experience level with respect to 
sequencing. Therefore, these observations are not likely 
the result of my inexperience with the sequencing protocols 
and procedures. The overall number of base pair changes 
from patient samples in series A was 48 in 40,095 base
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pairs sequenced (0.12%), while samples in series B had 12 
base pair changes in 23,085 base pairs sequenced (0.05%).
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Table 6. Comparison Between the Date of the Sequence and 
the Sequence Result
Sequences Demonstrating No Sequences Demonstrating a 
























Comparison of sequencing results versos the date sequenced, 
t Prior to August 20, 1999 
* After August 20, 1999
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□  Before August 20, 1999 ■  After August 20, 1999
©  20
1+ Base Pair Change(s) No Base Pair Changes
Figure 29. Graphical Representation of the Sequencing 
Results Versus the Date of Sequencing.
These results indicate that more of the sequences that 
showed 1+ base pair changes were performed after August 20, 
1999. Likewise, more of the sequences that showed no base 
pair changes were performed prior to August 20, 1999. This 
indicates that the high rate of base pair changes may be a 
direct result of the substitution of Taq Polymerase.




NEW INFORMATION ABOUT THE hBUBl GENE
Since the inception of this study, many advances have 
been made with regards to the status of the hBUBl gene in 
various cancers/cancer cell lines. The index cases were 
reported by Cahill et al., who found two of 19 (10.5%) 
colorectal cancer cell lines exhibited a mutation within 
hBUBl. The first mutation was a 197 base pair deletion 
spanning codons 76-141, and the second was a missense 
mutation (C-^A transition at codon 492 resulting in an amino 
acid change of Tyr->Ser) (Figure 30) . Both mutations were 
found to be heterozygous, with a wild type second allele. 
When either mutation was expressed in a cell, the cell 
changed to a CIN phenotype, indicating that the mutations 
were dominant negative (Cahill et al., 1998) . It is 
important to note that the original colorectal cancer cell 
lines that exhibited a hBUBl mutation all had a CIN 
phenotype and exhibited high levels of aneuploidy (30-50%) 
in many different chromosomes, including chromosomes 7 and 
8 (Cahill et al., 1998; Lengauer et al., 1997). This level
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of aneuploidy is about 10 times higher than the observed 
average aneuploidy in this study for chromosomes 7 or 8.
In addition, only one patient sample showed an elevated 
level of aneuploidy in both chromosomes 7 and 8. In 
contrast, the cell lines examined by Cahill et al., showed 
consistently high levels of aneuploidy in all chromosomes 
analyzed (Cahill et al., 1998; Lengauer et al., 1997).
Yamaguchi et al. studied 31 head and neck squamous cell 
carcinoma and lung cancer cell lines with respect to 
mutations within hBUBl, and found only one base pair change 
present (T->C transition at codon 220 with no amino acid 
change) (Figure 30). This implies that mutations in hBUBl 
within head and neck squamous cell carcinoma or lung cancer 
cell lines are rare, and do not contribute to the high 
levels of aneuploidy that is characteristic of these cell 
lines (Yamaguchi et al., 1999).
Imai et al. examined 32 sporadic digestive tract cancers 
for mutations within the hBUBl coding region, and found one 
heterozygous mutation within hBUBl in one rectal cancer 
case (A-^G transition at codon 950 with an amino acid change 
of Gly-^Ser) (Figure 30). This data indicates that 
mutations within hBUBl are not common in the sporadic 
digestive tract cancers (Imai et al., 1999).











Yamaguchi et al., 1999
CD1 NLS CD2
*






Oshima et al., 2000
Figure 30. Comparison of Mutation Locations for hBUBl.
The four studies that have shown the presence of a mutation 
within the hBUBl coding region are shown here. Each 
mutation is marked with the * symbol at the approximate 
codon location that the mutation occurred. None of the 
mutations occurred in the same location.
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Myrie et al. looked at 19 breast cancer cell lines, all 
of which were aneuploid, and found no mutations present in 
the hBUBl coding region. Therefore, mutations in hBUBl 
within breast cancer cell lines are a rare event.
Ohshima et al. analyzed ten cases of adult T-cell 
leukemia and eight cases of B-cell lymphoma for mutations 
in hBUBl, and found one mutation in one of the adult T-cell 
leukemia patients (G“̂ A transition at codon 250 with an 
amino acid change of Gly^Asp) (Figure 30) . Mutations in 
hBUBl were not common in either adult T-cell leukemia or 13- 
cell lymphoma, and most likely do not contribute to the 
highly complex karyotypes seen in patients with adult T- 
cell leukemia (Ohshima et al., 2000).
It is also interesting to note that Jaffrey et al. 
examined the stability at seven microsatellite markers on 
chromosome 2q (where hBUBl is located) in 32 colorectal 
cancers and 20 non-small cell lung cancers, both of which 
exhibit high levels of aneuploidy. The BUB1 locus was 
found to be allelically unstable in 62.5% of colorectal 
cancer samples examined. Instability can result in changes 
within the coding region, which affects gene transcription. 
In addition, the hBUBl sequence was analyzed in these 32 
colorectal cancer tumors, 20 non-small cell lung cancers, 
and 8 colorectal cancer cell lines, and no mutations were
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present. This indicates that mutations within hBUBl are 
most likely not responsible for the high levels of 
aneuploidy that is commonly seen in colorectal cancer 
tumors, non-small cell lung cancers and colorectal cancer 
cell lines (Jaffrey et al., 2000).
In combination, the data summarized above indicate that 
mutations in the hBUBl coding region in a variety of 
cancers and cancer cell lines are very rare occurrences.
The information from this study is in agreement with the 
above data, and showed that a mutation within hBUBl in 
samples from patients with aplastic anemia is also a rare 
occurranee.
FISH RESULTS
The presence of clonal cytogenetic abnormalities in 
patients with AA is evidence of a pre-leukemic state (Marsh 
and Geary, 1991). Some researchers have shown that 
cytogenetic analysis by FISH is more sensitive than 
karyotype analysis (Thurston et al., 1999; Socie et al., 
2000; Young, 1999; Young, 2000). Therefore, FISH may 
detect early clonal cytogenetic abnormalities normally 
missed by a karyotype analysis. Since monosomy 7 and 
trisomy 8 are common in MDS and ANLL (Socie et al., 2000),
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chromosomes 7 and 8 were chosen for FISH analysis in this 
study. Hypothetically, the presence of chromosomal 
aberrations may indicate a higher likelihood of later 
transformation to MDS or ANLL. These aberrations may be 
easier to detect using FISH.
The statistical analyses on the results obtained by FISH 
analysis on bone marrow samples from patients in series A 
(AA patients only), showed no statistically significant 
difference between the patient samples as a whole versus 
control samples with respect to the level of aneuploidy for 
either chromosome 7 or 8. There were certain patient 
samples that individually showed increased levels of 
aneuploidy in chromosome 7, chromosome 8 or a combination 
of both chromosomes. Seven of 46 patient samples (15.2%) 
showed increased levels of aneuploidy. Four of the seven 
patient samples (57.1%) showed newly detected aneuploidy 
that was previously unreported in a karyotype analysis.
FISH may be useful in detecting chromosomal abnormalities 
earlier within the disease progression. In this study,
FISH results were more than twice as sensitive in detecting 
cytogenetic abnormalities when compared to the results 
obtained by a karyotype analysis.
The level of aneuploidy in patient samples that showed 
statistically significant levels of aneuploidy ranged from
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3.33% to 12.07%. These values are relatively low when 
compared to literature values for aneuploidy levels found 
in colorectal cancer cell lines (30-50%). In addition, 
values reported by Lengauer et al. demonstrated a high 
level of aneuploidy in all chromosomes assayed, not 
selective aneuploidy in just one or two chromosomes. "CIN 
affects all chromosomes equally" (Lengauer et al., 1997), 
however, of the seven patient samples showing statistically 
significantly elevated levels of aneuploidy, only one 
patient sample showed an increased level of aneuploidy for 
both chromosomes 7 and 8. The remaining six patient 
samples showed selective aneuploidy in only one of the two 
chromosomes assayed.
The mitotic index, obtained to estimate the cell growth 
rate, was uniformly low and not statistically significantly 
different in a 2-sample t-test comparison of patient 
samples versus control samples (p=0.571). The patient 
samples in this study do not appear to be rapidly dividing, 
but neither do the control bone marrow samples. Cahill et 
al. (1998) demonstrated that the mitotic index was 
significantly reduced in cells that expressed a mutant 
hBUBl. The cells with wild-type hBUBl showed a mitotic 
index that was 90% of the control value, while cells with a 
mutant hBUBl showed a mitotic index that was 60% of the
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control value (Cahill et al., 1998). In comparison, the 
data from this study (series A patient samples only) 
indicated that the average patient MI was 0.44%, while the 
average control MI was 0.33%. These data are different 
from the data previously reported by Cahill et al. (1998). 
However, in the study by Cahill et al. (1998), pure
colorectal cancer cell lines were used, compared to the 
cells in this study, which were taken from patients with 
decreased bone marrow. The low mitotic index may be of 
importance when evaluating the hBUBl-specific RT-PCR 
results from the patient samples in this study.
RT-PCR RESULTS
The absence of h-BCTBI-specific RT-PCR products in patient 
samples from this study may have occurred as a direct 
result of low cell regeneration. In some samples, the 
intensity of the expected RT-PCR band varied, indicating 
that the level of hBUBl expression may vary from patient to 
patient. DNA microarray assays have detected that in 
yeast, BUB1 peaks during the G1 phase of the cell cycle 
(Spellman et al., 1998). Perhaps those patients who did 
not amplify any hBUBl RT-PCR product had a very low level 
of hBUBl expression, or had the majority of the cells not
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in the G1 phase of the cell cycle, so that the level of 
hBUBl was too low to be detected by conventional RT-PCR 
methods. The same concentration of RNA was used in all of 
the cDNA synthesis reactions, however different volumes of 
RNA were used in each reaction, depending on the 
concentration of the RNA. RT-PCR was successful in 
amplifying the hBC7B2-specific RT-PCR product in samples 
with an RNA concentration as low as 0 . 0 62p.g/p.l. On the 
contrary, no hBC7B2-specific RT-PCR product was detected in 
samples with an RNA concentration as high as 4.440p.g/y.l.
If hBUBl were expressed in dividing cells, one would 
expect successful amplification of the hBUBl RT-PCR product 
in all dividing cells. However, only a small portion of 
the patients assayed exhibited a RT-PCR product (21.7% of 
patient samples in series A and 30.1% of patient samples in 
series B), and only 60% of the control samples amplified 
the correct hBC7B2-specific RT-PCR product. Since part of 
the PCR verification included the synthesis of the 
complimentary DNA using a hBUBl oligonucleotide reverse PCR 
primer, the lack of amplification was most likely not due 
to incomplete cDNA synthesis. However, a complex secondary 
structure could have interfered with the cDNA synthesis 
since the samples were not heated to eliminate secondary 
structure prior to the reverse transcription reaction.
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Another explanation could be the presence of 
hypermethylatdon within the hBUBl promoter region, which 
may inhibit the expression of the gene. The presence of an 
actin RT-PCR product verifies that the overall RT-PCR 
reaction was successful. In addition, more control bone 
marrow samples need to be assayed to obtain a more accurate 
percentage of hBUBl-specific RT-PCR amplification. The 
investigation of the low amplification rate is deserving of 
further research.
SEQUENCING RESULTS
If aneuploidy were caused by a mutation within a mitotic 
spindle checkpoint gene, hBUBl would be a likely candidate 
based on early literature. Since hBUBl is required for the 
spindle checkpoint within the cell cycle, the lack of hBUBl 
function could hypothetically lead to the demise of the 
spindle checkpoint and premature entrance into anaphase 
before all chromosomes are properly aligned on the 
metaphase plate. It is also the most characterized of the 
group of genes which comprises the mitotic spindle 
checkpoint.
However, if a mutation in hBUBl did abrogate the function 
of the mitotic spindle checkpoint, one would expect to see
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consistent levels of aneuploidy in all chromosomes. It is 
highly unlikely that a mutation in hBUBl would target a 
specific chromosome, thereby enabling chromosome-specific 
aneuploidy to occur. In this study, aneuploidy levels for 
both chromosomes were not consistent.
With respect to the sequencing results obtained by this 
study, it is reasonable to conclude that the base pair 
changes seen after August 20, 1999 are not real, but are 
due to artifacts introduced at the PCR stage of the 
experiment. Using this assumption, I modified the 
presentation of the sequencing results (Table 7).
In Table 7, I assumed that all base pair changes found in 
patient samples analyzed after August 20, 1999 were 
artifacts. In addition, I have removed all base pair 
changes that did not result in an amino acid change (as 
this would probably not affect the function of the 
protein). This greatly reduces the number of potential 
mutations due to actual base pair changes.
The sample from patient #43 (adjusted) shows the presence 
of a base pair change at base pair 845, which is located
within the NLS coding region (Cahill et al., 1999). FISH
analysis failed to detect any significant amount of 
aneuploidy for either chromosome 7 or 8 for this patient.
Therefore, it is reasonable to conclude that the sample
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Table 7. Sequencing Results Adjusted for Taq-induc:ed PCR 
Artifact
Patient # BP# BP Change Amino Acid Change
43 845 G“>A Glu">Lys
82 632 G~>A Gly~>Arg
908 C~>T Gln-^stop
132 566 A-»G Thr-»Ala
136 731 A-»G Lys~>Glu
Corrected sequence results for patient samples in s eries A 
and series B. All samples listed were sequenced pr ior to 
August 20, 1999 and had a base pair change that res'ulted in 
an amino acid change. Note that none of the above 
sequencing results were confirmable.
Abbreviation: BP=base pair
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from patient 43 either 1) had no mutations within the CD1 
or NLS regions of hBUBl (existing base pair change is an 
artifact), 2) the base pair change present does not alter 
the function of the BUB1 protein, or 3) hBUBl does not play 
a direct role in the creation of aneuploidy.
The sample from patient #82 shows two base pair changes, 
located at base pairs 632 and 908, both of which are 
located in the NLS region. If the base pair change at 
number 908 were real, it would induce the formation of a 
stop codon. This would lead to the translation of a 
truncated protein, which may be unable to function. A 
mutation in the NLS region may affect the ability of the 
BUB1 protein to localize to the nucleus. Since BUB1 is 
active at the kinetochore, it must be able to travel into 
the nucleus from the cytoplasm to be able to function. In 
this patient sample, statistically significantly elevated 
levels of aneuploidy were not observed for either 
chromosome 7 or 8. In addition, the majority of the 
sequence data obtained for the sample from patient 82 
showed no base pair changes present. It is therefore 
reasonable to conclude that due to the high probability of 
Taq-induced PCR artifact and because this patient did not 
exhibit any signs of a loss of the mitotic spindle
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checkpoint (the appearance of aneuploidy), the base pair 
changes seen are most likely artifactual.
Samples from patients #132 and #136 did not undergo FISH 
analysis. Regardless, it is possible to draw similar 
conclusions with respect to the sequencing results from 
these patient samples, and assume that the base pair 
changes seen are most likely the result of Taq-induced PCR 
artifact.
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CHAPTER V  
CONCLUSIONS
1. New FISH data on AA patient samples
This study showed that aneuploidy in patients with 
aplastic anemia is a rare event, with only 7 of 46 (15.2%) 
patient samples displaying aneuploidy for chromosome 7 
and/or 8. It is of importance to note that the percent 
occurrence may not be synonymous with the percent of new 
cytogenetic events, as clonal selection may play a role in 
the expansion of a cell type. It is possible that the 
aneuploidy detected represents early clonal selection for 
the apparent cytogenetic abnormalities, which may increase 
over time.
2. FISH was approximately twice as sensitive as 
conventional cytogenetic analysis by karyotype
In this study, FISH detected more than twice as many 
cytogenetic abnormalities than the karyotype analysis.
FISH may be beneficial in detecting early cytogenetic 
abnormalities.
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3. African-American males showed a statistically 
significantly elevated level of monosomy 8
In. a multivariate ANOVA statistical analysis, African- 
American males showed a greater likelihood of exhibiting 
monosomy 8 (p=0.016) . These results should be viewed with 
caution due to the low sample size number, but may be 
beneficial in the future if perhaps African-American males 
have a genetic variant making them more susceptible to 
developing AA.
4. One patient showed statistically significantly elevated 
levels of aneuploidy for both chromosomes 7 and 8
One patient sample exhibited high levels of aneuploidy 
for both chromosomes 7 and 8, which is more characteristic 
of a CIN phenotype. However, this appears to be a rare 
occurrence within patients with AA.
5. Two patients showed the presence of an unusual insertion 
within the forward primer area of hBUBl
Two patients (#42 and #52) exhibited an insertion within 
the forward primer area in hBUBl, which would be predicted 
to inhibit the complete translation of the protein product. 
If verified, these insertions would suggest a loss of 
normal hBUBl function, and perhaps an abrogated mitotic
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spindle checkpoint. Verification is needed to ensure that 
the insertions are not due to faulty ligation with the 
plasmid vector or errors with the polymerase activity. The
sample from patient #52 did show a statistically 
significantly elevated of aneuploidy, however the 
aneuploidy does not appear to be due to the insertion, as 
it would likely been seen in both patient samples.
6. Preliminary sequencing results indicated that base pair 
changes in hBUBl within AA patients are rare occurrences
The majority of patient samples did not exhibit any true 
base pair changes within the hBUBl CD1 and NLS regions.
This correlates to recent data from other laboratories 
showing that mutations in hBUBl in a variety of cancers and
cancer cell lines rarely occur. This suggests that the 
aneuploidy seen in these patient samples and in other 
studies may not be due to a mutation within the mitotic 
spindle checkpoint gene hBUBl. However, there are many 
possible causes of aneuploidy, with mutations in a mitotic 
spindle checkpoint gene being only one of the different 
pathways. Further investigation and verification is 
required to establish a more concrete conclusion.
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I D  * D i a g n o s i s S e x R a c e C y t o g e n e t i c s
17 MDS F W 46, xx
18 MDS M W 46,xy,del(20) (qll.2ql3.3) [4]/46,xy[19]
21 MDS/5q— F w 46,xx,del(5) (q22q33) [10]/46,xx[10]
23 5q- F w 46,xx,del(5)(ql3q33)[17]/47,xx,t8[3]
25 AA M w 46, xy
26 Thrombocytosis M w 4 6,xy, del(17)t(?13;17) (ql4;pll,2) [13]/46,xy [81
27 MDS M 46,xy,-7[14]/46,xy[16]
28 MDS M w 46, xy
29 AA M H 46, xy
30 AA F H insufficient
31 AA M A 46, xy
32 AA M 46, xy
33 AA M H 46, xy
34 AA/PRCA M W 4 6,xy[3 ]
35 AA M W 46,xy[30]
36 MDS M W 46,xy[30]
37 AA M W 46,xy[29]
38 MDS/5q— F 46,xx,del(5) (ql5q35) [3]/46,xx[3]
39 AA M A 46, xy
40 AA F W 46,xx[31]
41 AA F H 46, xx
42 AA M B 46,xy[30]
43 AA/Porvovirus F W 46,xx[30]
44 RA/5q— F W 46,xx,del(5) (ql5q35.1) [20]
45 MDS M W 46, xy
46 MDS F 46,xx[30]
47 MDS M W 46,xy[30]
48 MDS M W 46, xy
49 Porvovirus F 46, xx
50 AA/Trisomy 8 F W TRI8
51 AA F 46, xx
52 AA/Trisomy 8 M W 47,xy,+8[13]/4 6,xy[7]
53 MDS M W insufficient
54 MDS M W 46, xy
55 AA/PNH F W 46,xx,inv(9)(pllql3)c
56 MDS M W 46,xy[30]
57 AA M W 46, xy
58 AA M A 46,xy
59 AA M A insufficient
60 AA F W 46,x,ins(x;1)(pll.4;q21q42.3)[9]/46,xx[41]
61 5q— M W 46.xy,del (51 (q3lq35) . lnvC9) (pll-2ql3) [81/4 6.xy.lnv(9) (piI-2ql3l (13]
62 MDS M W 46,xy[30]
63 MDS M A 46,xy
64 AA F H 46,xx[30]
65 AA F H 46,xx[30]
66 RAEB M W 47,xy,+21[3] /48, iden,+13[2]/46,xy[17]
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I D  * D i a g n o s i s S e x R a c e C y t o g e n e t i c s
67 PRCA F W 46, xx
68 MDS/RAEB M W 46, xy [30]
69 AA M H 46,xy
70 AA/Hepatitis C M W 46,xy[30]
71 Pancytopenia M W 46,xy,del(20) (qll.2ql3) [12]/46,xy[10]
72 PNH M 46, xy
73 AA F 46,xx[30]
74 MAA/PNH M H 46,xy,del(20) (qll.2ql3.3) [2]/46,xy[31]
75 MyeloproliferativeDisease M W 46,xy,del(20) (qll.2ql3.3) [5]/46,xy[15]
76 Neutropenia F W 46,xx[30]
77 Pancytopenia/AA F W 46, xx [30]
78 RA/5q— F W 46,xx,del(5)(q22q33)[12]/46,xx[2]
79 MDS M B 46,xy
80 LGL M W 46, xy
81 AA M B 46, xy
82 AA M H 46,y,t(x;8)(p22.I;q24.1)
83 Moderate AA F W 46,xx[30]
84 MDS M W 46,xy,-7,-15,-17[1]/46,xy[49]
85 AA/PNH F W 46, xx
86 AA M H 46, xy
87 SAA F B 4 6, xx
88 SAA M W 46, xy [30]
89 AA F W 46, xx
90 Moderate AA F H 46, xx
91 MDS M W 4 6,xy,del(11) (q23q2S) [14I/46,xy,dup(l)q(4 4ql2) ,del(17) (d 11-2d 12)r4)/46.xvr21
92 MDS F W 46, xx
93 MDS M W 4 6, xy
94 Pancytopenia post acute Procoevlocvtic leukemia M W 46,xy,del (20) (qll.2ql3.3) [ 16]/47, idem,+8[3]/46,xy[1]
95 AA F W 4 6 , XX
96 Probable progression to leukemia M W 4 6, xy
97 MDS M
98 AA F B 46,xx[30]
99 AA/Trisomy 8 M W 47.xy,+ 8 [14]/46,xy[7]
100 MDS F A
101 AA/ PNH/LGL M B 45,x,-y[14]/46,xy[6]
102 MDS M W 46, xy [30]
103 MDS M W 46,xy[27]
105 AA F W 4 6 ,xx[3 0]
106 AA/PNH M A 4 6, xy
107 MDS F W 46, xx
108 MDS M W 46, xy [30]
109 MDS M B 46,xy,del(11)(q21q23)[10]/46,xy[10]
110 MDS F 46,xx[30]
111 AA M 46,xy[30]
112 Anemia M W 46, xy
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113 Moderate AA F W 46, xx
114 MDS F W insufficient
115 AA F w 46, xx
116 AA F A 46,xx[30]
117 AA F H 46,xx[30]
118 MDS M W
119 AA M 46,xy,inv(9) (pllql3)c
120 MDS F 46, xx
121 AA M W 46,xy
122 AA M
123 Myeloproli f©rativ© disease M 46,xy,t(5:12)(q33;pl3)[7]/46,xy[13]
124 PNH M B
125 PRCA M W
126 MDS M H 47,xy,+8[7]/46,xy[13]
127 Thrombocytopenia F 46, xx
128 AA F W 46,xx[30]
129 AA F W 46,xx[30]
130 AA/PNH F W 46, xx
131 MDS M W
132 Liver Transplant F H
133 MDS M W
134 new MDS M W
135 AA M H
136 AA F W
137 AA F W 46,xx[30]
138 Anemia M B
139 AA F 46, xx
140 MDS F W
141 AA M W
142 AA F W 46,xx[30]
143 MDS M W
144 AA Hepatitis/aplasia M B
145 AA V  MDS F A
146 AA v MDS M W 46,xy[21]
147 AA M W 46, xy [30]
148 AA M W
149 MDS M W
150 RAEB M
151 PRCA M
152 Thrombocytopenia M W
153 AA/PNH F W 46, xx
154 PNH W
155 MDS M W
156 MDS M W
157 AA M W 46,xy[30]
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158 AA F W
159 MDS F W
160 MDS
161 Pancytopenia F w
162 AA A
163 AA F W
164 Acute Pancytopenia F W
165 AA M W
166 AA M W 46,xy[30]
167 AA F 48,xxxc,+8[5]/47,xxxc[15]
168 AA F trisomy 8




173 PNH M W
174 Hypoplastic Anemia M A
175 AA M H
176 AA M B
177 PNH F B
178 RA F W
179 AA F B
180 AA F H
181 AA M H
182 AA F W
183 AA F
184 MDS M W
185 AA F
186 MDS M W
188 Pancytopenia M W
190 Pancytopenia F W
191 AA M W
192 AA M B




197 PNH/AA F W
198 MDS M W
199 MDS M W
200 new MDS F
201 AA M A
202 AA M B
203 MDS F W
204 AA F
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205 A A M H
206 MDS F W
207 A A M
208 AA
209 A A M H
210 Pancytopenia M
211 AAvMDS (RA) M
212 AA F W
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ID # BUB tetla R-cDKA. 7(1) 7(2) 7(3) 8(1) 8(2) 8(3) Treatment
17 no + - new; evaluate for ATG
18 no + - new, evaluate for ATG
21 no + - 1 yr f/u non-responsive to ATG
23 no + - failed ATG
25 no + - new patient. No treatment
26 no + -
27 1.2 + + new patient. No treatment
28 no + - EPO/G-CSF nonrespomder 1 yr ago
29 no n/a n/a 4 294 2 2 295 3 Cytoxan/CSA responder
30 no + - post liver transplant. No treatment
31 no + - 4 296 0 10 289 1 no treatment
32 no n/a n/a Danzol recently
33 no n/a n/a 3 296 1 11 289 0 ATG/CSA Relapased on CSA
34 1.2 n/a n/a None?
•35 no + - Treated with ATG & CSA
36 1.2 + + 6mo f/u Post ATG non-responder
37 no + - 9 291 0 7 292 1 6mo f/u Post cytotox±n?/CSA Responder
38 no + - 1 yr f/u failed ATG
39 no n/a n/a 2 297 1 7 289 4 5 yr f/u post ATG/CSA responder
40 no + - 10 287 3 7 291 2 6 yr f/u on CSA post ATG/CSA relapsed
41 no n/a n/a 3 295 1 5 293 2 CSA platelet fx dependent?, ATG, 1L-3, Neuoooem?
42 1.2 + + 8 292 0 4 295 1 4 years post ATG/CSA responder
43 1.2 + -t- 9 289 2 7 290 3 ATG no response
44 no + - no treatment
45 1.2 n/a n/a new
46 1.2 + -l- new
47 no + - new ?- NR
48 no + - new
49 no + - none
50 no + + ATG/CSA, on ? CSA
51 no + - ATG/CSA responder
52 1.2 + + 8 290 2 1 238 61 ATG/CSA responder now relapsed
53 no + - ATG/CSA responder
54 no + - ATG/CSA non-responder
55 no + - ATG/CSA responder
56 no + - Growth factor non responder
57 no + - 7 292 1 4 293 3 ATG,CSA.De??responder
58 no + - 6 294 0 16 284 0 no treatment
59 no + - no treatment
60 no + - 5 295 0 9 289 2 2yr post ATG/CSA respomder
61 no + - Failed ATG
62 no + - Failed 5-AZA Failed Neumega?
63 no + - never treated
64 no + - 4 295 1 6 292 2 ATG/CSA iyr post tr. On CSA relapsed
65 no + - ATG/CSA responder lyr
66 no + - None
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ID # BUB R-cDMA. 7(1) 7(2) 7(3) 8(1) 8(2) 8(3) Treatment
67 no + - lyr post ATG
68 no + - None
69 no + - 6mo post cyotoxin?/CSA
70 no neg - yr f/u ??
71 no + - None
72 1.2 + + None
73 no + - ATG/CSA Relapsed
74 no neg - ATG Responder
75 no + - None
76 no + - None
77 no + - 5 295 0 4 294 2 C S A  and Prednisone & EPO
78 no + - transient responder to ATG, s/p CSA —  -> MR
79 no neg - ATG responder then relapse, retreat ATG — > normal counts
80 1.2 n/a n/a None
81 no + - 7 293 0 7 291 2 None
82 1.2 n/a n/a 9 290 1 4 292 4 6 months post ATG/CSA
83 no + - None
84 1.2 n/a n/a ATG
85 no + - 3 295 2 7 284 8 CSA
86 no + - 2 297 1 5 294 0 1 year post cytoxen, 2 years post ATG
87 no + - 7 293 0 11 284 5 ATG/CSA 6 mo post tx, non responder
88 no + - 6 294 0 6 290 4 ATG/CSA 6 mo post tx, responder
89 no + - ATG/CSA, Davarol, non responder
90 1.2 n/a n/a 5 293 2 0 297 3 none
91 no n/a n/a l.Oyr F/U ATG,
92 no + - never treated
93 no + - never treated
94 no neg - chemotherapy
95 no + - 5 294 1 1 298 1 18mo post A T G / C S A  responder
96 1.2 n/a n/a none
97 no neg - none
98 no + - 7 292 1 4 289 7 lyear post cytoxen/CSA
99 no + - 2 298 0 8 204 88 1 1/2 year post ATG/CSA
100 no neg - nonresponder 10/95
101 no + - 8 292 0 10 286 4 6mo post ATG/CSA non responder
102 1.2 n/a n/a 6mo f/u non responder A T G
103 no + - failed - new MDS
105 no + - ATG/CSA responder - now cts dropping
106 no + - no treatment
107 no + - no treatment - to start CSA today
108 1.2 n/a n/a no treatment
109 no + - failed ATG 1 year f/u
110 1.2 n/a n/a none
111 no + - 12 286 2 13 279 8 none
112 no + - none
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ID * BOB R-cDKA 7(1) 7(2) 7(3) 8(1) 8(2) 8(3) Treatment
113 no + - 3 254 2 7 251 1 none
114 no + - multiple Amifostine etc
115 no + - 3 296 1 4 292 4 ATG/CSA lyr post tr. Responder, relaose now?
116 no + - 8 289 3 3 287 10 not treated
117 1.2 n/a n/a 8 292 0 9 288 3 ATG/CSA relapsed currently on CSA
118 1.2 n/a n/a never treated
119 no + - None
120 1.2 n/a n/a Untreated
121 1.2 n/a n/a 7 293 0 5 294 1 ATG/CSA 6 mo ago, responder
122 no + - , 1 yr ago Cytoken/CSA, responder
123 no + - none
124 1.2 + + new patient. No treatment
125 1.2 + + new patient. No treatment
126 1.2 + + new patient. No treatment
127 no + - none
128 no + - 6 110 0 14 100 2 ATG, IVIG, Steroids, spleenectomy
129 1.2 + + 2 296 1 0 299 0 none
130 no + - 4 161 0 2 163 0 ATG/CSA responder
131 no + - EEO
132 1.2 n/a n/a ATG 6mo post on FK506
133 1.2 n/a n/a 6mo f/u CSA
134 1.2 + + EPO
135 1.2 + + Relapsed 1 1/2 years non-responder, ATG/CSAx2
136 1.2 n/a n/a ATG/CSA relapsed, CSA dependent
137 1.2 n/a n/a 7 292 1 6 287 7 none
138 1.2 + + none
139 no + - 1 299 0 2 297 1 ATG/CSA Relapsed on CSA
140 1.2 n/a n/a new patient. No treatment
141 1.2 n/a n/a 6yr, post ATG/CSA
142 no + - 1 298 1 8 292 0 new patient. No treatment
143 no + - Untreated
144 1.2 + + Cytoxan/CSA I yr post treatment Resoonder
145 no + - None
146 no + - 4 295 1 3 291 6 new patient. No treatment
147 no + - 4 296 0 8 290 2 new patient. No treatment
148 1.2 + + new patient. No treatment
149 1.2 + + new patient. No treatment
150 no + - ATG non-responder
151 no + - new patient. No treatment
152 no + - new patient. No treatment
153 1.2 + + 1 297 2 8 291 1 new patient. No treatment
154 no + - new patient. No treatment
155 1.2 + + 6 mo f/u CSA responder
156 1.2 n/ a n/a EPO
157 no + - 3 297 0 6 294 0 lyr post cytoxen/csa, 6mo post ATG/CSA, no response for both
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ID * BOB tuntin R-cDHA. 7(1) 7(2) 7(3) 8(1) 8(2) 8(3) Treatment
158 1.2 + + 11 years post treatment
159 no + - none
160 no + - none
161 no + - 7 years, none
162 no + - ATG/CSA non—responder
163 no + - ATG/CSA on ATG
164 no + - N Bupogen
165 no + - ATG/CSA 8 years post responder, hepatitis C
166 no + - 9 290 1 4 296 0 new patient, no treatment
167 no + - 5 295 0 8 291 1 ATG/Decadurobulie? ?
168 no + - 5 295 0 12 257 31 ATG/CSA
169 no + - 2 298 0 3 294 3 ATG/CSA, cytotoxin
170 1.2 n/a n/a none
171 no + - new patient, no treatment
172 no + - new patient, no treatment
173 1.2 + + none
174 no + - none
175 no + - 1 year post Cytoxan/CSA
176 no n/a n/a ATG/CSA x2
177 1.2 + + none
178 1.2 + + none
179 1.2 + + ATG/CSA non—responder
180 1.2 + + ATG/CSA x3 approx 1 year from ATG responder
181 no + - none
182 no + - ATG/CSA
183 1.2 + + Cytotoxin non—responder
184 no + - none
185 no + - ATG/CSA
186 no + - none
188 no + - none
190 no n/a n/a none
191 1.2 n/a n/a ATG/cSA 1 year post treatment
192 no + - none
193 1.2 n/a n/a none
194 no + -
195 no + -
196 1.2 n/a n/a
197 no + -
198 no + - ATG failed
199 no + - ATG failed
200 no + - None
201 no + - 6 yrs post ATG/CSA Responder
202 1.2 + + Cytoxan?CSA 6.5mo response?
203 no + - None
204 no + - ATG/CSA
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ID * BOB festia R-ormx 7(1) 7(2) 7(3) 8(1) 8(2) 8(3) Treatment
205 1.2 n/a n/a
206 no + -
207 no + -
208 no + -
209 no + -
210 no + -
211 no n/a n/a
212 no + - ATG/CSA
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